WO2011008092A2 - Gram-positive bacteria specific binding compounds - Google Patents

Gram-positive bacteria specific binding compounds Download PDF

Info

Publication number
WO2011008092A2
WO2011008092A2 PCT/NL2010/050456 NL2010050456W WO2011008092A2 WO 2011008092 A2 WO2011008092 A2 WO 2011008092A2 NL 2010050456 W NL2010050456 W NL 2010050456W WO 2011008092 A2 WO2011008092 A2 WO 2011008092A2
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
antibody
functional equivalent
functional
immunoglobulin chain
Prior art date
Application number
PCT/NL2010/050456
Other languages
French (fr)
Other versions
WO2011008092A3 (en
WO2011008092A4 (en
Inventor
Tim Beaumont
Mark Jeroen KWAKKENBOS
Eric J. Brown
John Hiroshi Morisaki
Wouter L.W. Hazenbos
Sanjeev Mariathasan
Kimberly Kajihara
Yi Xia
Original Assignee
Aimm Therapeutics B.V.
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI201031701T priority Critical patent/SI2454284T1/en
Priority to NZ598063A priority patent/NZ598063A/en
Priority to MX2014012186A priority patent/MX350234B/en
Priority to ES10734844.3T priority patent/ES2673323T3/en
Priority to SG2012002622A priority patent/SG177653A1/en
Priority to EA201390967A priority patent/EA031447B1/en
Priority to DK10734844.3T priority patent/DK2454284T3/en
Priority to CN201080041138.6A priority patent/CN102666583B/en
Priority to CA2768204A priority patent/CA2768204A1/en
Priority to BR112012000953A priority patent/BR112012000953A8/en
Priority to PL10734844T priority patent/PL2454284T3/en
Priority to EP10734844.3A priority patent/EP2454284B1/en
Priority to JP2012520555A priority patent/JP6192294B2/en
Priority to AU2010271582A priority patent/AU2010271582B2/en
Application filed by Aimm Therapeutics B.V., Genentech, Inc. filed Critical Aimm Therapeutics B.V.
Priority to KR1020127003839A priority patent/KR101832201B1/en
Publication of WO2011008092A2 publication Critical patent/WO2011008092A2/en
Publication of WO2011008092A3 publication Critical patent/WO2011008092A3/en
Publication of WO2011008092A4 publication Critical patent/WO2011008092A4/en
Priority to IL217497A priority patent/IL217497A/en
Priority to ZA2012/00363A priority patent/ZA201200363B/en
Priority to IL238074A priority patent/IL238074A/en
Priority to IL242207A priority patent/IL242207A0/en
Priority to AU2016250398A priority patent/AU2016250398B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Definitions

  • the invention relates to the fields of biology, immunology and medicine.
  • Gram-positive microorganisms cause the majority of systemic infections.
  • Staphylococcus aureus S. aureus
  • About 20% of the population is a long-term carrier of S. aureus.
  • S. aureus can cause a range of illnesses from minor skin infections, such as pimples, impetigo (may also be caused by Streptococcus pyogenes), boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome and abscesses, to life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, Toxic shock syndrome (TSS), and septicemia.
  • TSS Toxic shock syndrome
  • aureus is capable of infecting all kinds of organs and tissues. S. aureus infections occur in immunocompetent as well as immune compromised people. About 50% of the infections in US intensive care units are caused by this pathogen. Three hundred thousand S. aureus infections per year, resulting in 12,000 deaths, are reported in the US (see also Moran et al. NEMJ 355, 666-674 (2006)).
  • MRSA Methicillin-resistant S. aureus
  • the present invention provides antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof capable of specifically binding Staphylococcus species in their natural context. Therefore, they are useful for counteracting and/or preventing and/or diagnosing disorders related to the presence of Staphylococcus species. Preferably, S. aureus is counteracted. In a particularly preferred embodiment, MRSA is counteracted. Another preferred Staphylococcus species which is counteracted is Staphylococcus epidermidis.
  • Staphylococcus epidermidis is usually non-pathogenic, but patients with a compromised immune system are often at risk for developing an infection. Infections can be both hospital and community acquired, but they are more of a threat to hospital patients. Most susceptible to infection with S. epidermidis are intravenous drug users, newborns, elderly, and those using catheters or other artificial appliances. Infections are associated with intravascular devices (prosthetic heart valves, shunts, etc.) but also commonly occur in prosthetic joints, catheters, and large wounds.
  • Symptoms include fever, headache, fatigue, anorexia and dyspnea.
  • the present invention provides isolated or recombinant human antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof capable of specifically binding Staphylococcus species.
  • Human antibodies and functional parts according to the invention are capable of binding Staphylococcus species in its natural context, so that various Staphylococcus species are counteracted upon administration of said antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof.
  • Said human antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof are therefore particularly suitable for treatment or prevention of infection by such Staphylococcus species.
  • Said human antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof according to the invention are more suitable for therapeutic and/or prophylactic use for human individuals, as compared to chimeric antibodies, because of the absence of non-human sequences. This significantly reduces the risk of adverse side effects.
  • One particularly preferred antibody according to the present invention is the antibody designated "Fl", which has heavy chain and light chain variable domain sequences as depicted in Figure 1.
  • the term “Fl” as used herein encompasses all Fl antibodies, for instance isolated or recombinantly produced Fl. Recombinantly produced Fl is herein also called “rFl”.
  • the CDR sequences of Fl, which in particular contribute to the antigen-binding properties of Fl, are also depicted in Figure 1.
  • Antibody Fl is fully human, is capable of specifically binding Staphylococcus species such as S. aureus and S. epidermidis and is therefore preferred for therapeutic use for human individuals.
  • antibody Fl is capable of binding whole bacteria in vivo as well as in vitro. Further provided is therefore an isolated or recombinant human antibody or a functional part thereof, which is capable of specifically binding S. aureus and/or S. epidermidis. Furthermore, antibody Fl is capable of binding to bacteria that have been grown in infected tissue of, for example, an animal. Provided is therefore an isolated antibody that binds to in vivo-grown S. aureus, wherein "in vivo-grown” is defined as grown in infected tissue of an animal during infection with S. aureus. Also provided is an isolated, recombinant or synthetic immunoglobulin chain or functional equivalent thereof comprising at least one CDR sequence of a human immunoglobulin variable region which is specific for S. aureus and/or S. epidermidis.
  • a functional part of an antibody is defined as a part which has at least one shared property as said antibody in kind, not necessarily in amount. Said functional part is capable of binding the same antigen as said antibody, albeit not necessarily to the same extent.
  • a functional part of an antibody preferably comprises a single domain antibody, a single chain antibody, a nanobody, an unibody, a single chain variable fragment (scFv), a Fab fragment or a F(ab')2 fragment.
  • a functional part of an antibody is also produced by altering an antibody such that at least one property - preferably an antigen-binding property - of the resulting compound is essentially the same in kind, not necessarily in amount. This is done in many ways, for instance through conservative amino acid substitution, whereby an amino acid residue is substituted by another residue with generally similar properties (size, hydrophobicity, etc), such that the overall functioning is likely not to be seriously affected.
  • a heavy chain of an antibody is the larger of the two types of chains making up an immunoglobulin molecule.
  • a heavy chain comprises constant domains and a variable domain, which variable domain is involved in antigen binding.
  • a light chain of an antibody is the smaller of the two types of chains making up an immunoglobulin molecule.
  • a light chain comprises a constant domain and a variable domain. The variable domain is, together with the variable domain of the heavy chain, involved in antigen binding.
  • Complementary- determining regions are the hypervariable regions present in heavy chain variable domains and light chain variable domains.
  • the CDRs of a heavy chain and the connected light chain of an antibody together form the antigen-binding site.
  • a functional equivalent of an immunoglobulin chain is defined herein as an artificial binding compound, comprising at least one CDR sequence of an immunoglobulin chain
  • the present invention provides the insight that the CDR sequences depicted in Figure 1 provide desired binding characteristics
  • a skilled person is well capable of generating variants comprising at least one altered CDR sequence. For instance, conservative amino acid substitution is applied.
  • an antibody or functional part is provided comprising a CDR sequence which is at least 70% identical to a CDR sequence as depicted in Figure 1, so that the favorable binding characteristics of Fl are at least in part maintained or even improved.
  • a CDR sequence as depicted in Figure 1 is preferably altered such that the resulting antibody or functional part comprises at least one improved property, such as for instance an improved binding affinity, selectivity and/or stability, as compared to Fl.
  • Variant antibodies or functional parts thereof comprising an amino acid sequence which is at least 70% identical to a CDR sequence as depicted in Figure 1 are therefore also within the scope of the present invention.
  • Various methods are available in the art for altering an amino acid sequence. For instance, a heavy chain or light chain sequence with a desired CDR sequence is artificially synthesized.
  • a nucleic acid sequence encoding a CDR sequence is mutated, for instance using random - or site-directed - mutagenesis.
  • the invention therefore provides an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof, which comprises:
  • a heavy chain CDR2 sequence comprising a sequence which has at least 70% sequence identity to the sequence SINNGNNPYYARSVQY (SEQ ID NO:2), and/or - a heavy chain CDR3 sequence comprising a sequence which has at least 70% sequence identity to the sequence DHPSSGWPTFDS (SEQ ID NO:3).
  • an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof which comprises:
  • a light chain CDRl sequence comprising a sequence which has at least 70% sequence identity to the sequence RASENVGD WLA (SEQ ID NO:4), and/or
  • KTSILES SEQ ID NO:5
  • a light chain CDR3 sequence comprising a sequence which has at least 70% sequence identity to the sequence QHYXRFPYT, wherein X is I or M (SEQ ID NO:6).
  • CDR sequences are the CDR sequences of antibody Fl; VH IgHV3-23 and VL IgKVl-5, and variants thereof. Binding compounds comprising CDR sequences with at least 70% sequence identity to Fl CDRs are particularly suitable for counteracting and/or preventing (the effects of) infections by S. aureus and/or S. epidermidis. It was found that a variant of Fl, comprising VH IgHV3-23 and VL IgKVl-5, in which the isoleucine in light chain CDR3 of the light chain was altered to a methionine, was still capable of specifically binding Staphylococcus species such as S. aureus and S. epidermidis.
  • a binding compound according to the invention comprises a CDR sequence which is at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 86%, more preferably at least 87%, more preferably at least 88%, more preferably at least 89%, more preferably at least 90% identical to at least one of the CDR sequences depicted in Figure 1.
  • a binding compound according to the invention comprises a CDR sequence which is at least 91%, more preferably at least 92%, more preferably at least 93%, more preferably at least 94%, more preferably at least 95% identical to at least one of the CDR sequences depicted in Figure 1.
  • the particularly preferred antibody Fl comprises CDR sequences which consist of the CDR sequences depicted in Figure 1.
  • a particularly preferred embodiment according to the invention thus provides an isolated, synthetic or recombinant antibody or a functional equivalent thereof which is capable of specifically binding S.aureus and/or S. epidermidis and which comprises:
  • a binding compound which comprises the heavy chain CDRl and CDR2 sequences and the light chain CDRl and CDR2 sequences as depicted in Figure 1, or sequences that are at least 70%, preferably at least 75%, more preferably at least 80%, more preferably at least 81%, more preferably at least 82%, more preferably at least 83%, more preferably at least 84%, more preferably at least 85% identical thereto.
  • an isolated, synthetic or recombinant antibody or a functional part thereof or an immunoglobulin chain or a functional equivalent thereof which comprises a heavy chain CDRl sequence comprising a sequence which is at least 70% identical to the sequence RFAMS (SEQ ID NO:1) and a heavy chain CDR2 sequence comprising a sequence which is at least 70% identical to the sequence SINNGNNPYYARSVQY (SEQ ID NO:2) and a light chain CDRl sequence comprising a sequence which is at least 70% identical to the sequence RASENVGDWLA (SEQ ID NO:4) and a light chain CDR2 sequence comprising a sequence which is at least 70% identical to the sequence KTSILES (SEQ ID NO:5).
  • Said binding compound preferably comprises CDR sequences which are at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 86%, more preferably at least 87%, more preferably at least 88%, more preferably at least 89%, more preferably at least 90%, more preferably at least 91%, more preferably at least 92%, more preferably at least 93%, more preferably at least 94%, most preferably at least 95% identical to the above mentioned heavy chain CDR sequences and light chain CDR sequences.
  • said binding compound also comprises a heavy chain CDR3 sequence comprising a sequence which is at least 70% identical to the sequence DHPSSGWPTFDS (SEQ ID NO:3), and/or a light chain CDR3 sequence comprising a sequence which is at least 70% identical to the sequence QHYXRFPYT, wherein X is I or M (SEQ ID NO:6).
  • a binding compound comprising the above mentioned heavy chain CDRl, CDR2 and CDR3 sequences as well as the above mentioned light chain CDRl, CDR2 and CDR3 sequences is also provided.
  • an immunoglobulin chain or functional equivalent thereof comprising at least one CDR sequence of a human immunoglobulin variable domain which is specific for Staphylococcus species. Further provided is thus an isolated, recombinant or synthetic immunoglobulin chain or functional equivalent thereof comprising at least one CDR sequence of a human immunoglobulin variable region which is specific for
  • a human antibody is provided.
  • said at least one human CDR sequence or at least one sequence in at least one of the framework regions is optimized, preferably in order to improve binding efficacy or stability. This is for instance done by mutagenesis experiments where after the stability and/or binding efficacy of the resulting compounds are preferably tested and an improved binding compound is selected.
  • optimizing CDR sequences in order to improve binding efficacy or stability it is often advantageous to optimize at least one sequence in at least one of the framework regions. This is preferably done in order to improve binding efficacy or stability.
  • Framework sequences are for instance optimized by mutating a nucleic acid molecule encoding such framework sequence where after the characteristics of the resulting antibody— or functional part— are preferably tested. This way, it is possible to obtain improved antibodies or functional parts.
  • human germline sequences are used for framework regions in antibodies or functional parts thereof or immunoglobulin chains or functional equivalents according to the invention. The use of germline sequences preferably minimizes the risk of immunogenicity of said antibodies, immunoglobulin chains or functional equivalents or parts, because these sequences are less likely to contain somatic alterations which are unique to individuals from which the framework regions are derived, and may cause an immunogenic response when applied to another human individual.
  • Antibodies or functional parts thereof or immunoglobulin chains or functional equivalents thereof comprising a heavy chain amino acid sequence which has at least 70% sequence identity to the heavy chain sequence as depicted in Figure 1 are also provided.
  • Such heavy chain sequence provides desired binding properties, as evidenced by antibody Fl.
  • light chain amino acid sequences which have at least 70% sequence identity to the light chain sequence as depicted in Figure 1, and a light chain sequence in which an isoleucine in CDR3 is altered to methionine also provide desired binding properties, as evidenced by antibody Fl, and a variant of antibody Fl comprising said alteration.
  • an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention having a heavy chain sequence comprising a sequence which has at least 70% sequence identity to the sequence
  • antibody variants include antibodies or functional parts or immunoglobulin chains or functional equivalents according to the invention, having a heavy chain sequence comprising the sequence
  • An antibody or functional part or immunoglobulin chain or functional equivalent thereof according to the invention specifically binds to proteins comprising a serine- aspartate (SD) repeat.
  • SD repeat (Sdr) proteins are cell-surface-associated proteins that are present in several bacteria such as Staphylococcus species. Sdr proteins in general comprise an amino-rerroinal signal sequence, a functional domain caiied Hio A region, an Sl) rops-ar region, a cell wall- spanning region, a LPXTG morif, a hydrophobic meinbrane-spjnnmg domain, and a series of positively charged residues.
  • the LFXTG m ⁇ tif is the target of a transpeptidase that cleaves the m ⁇ tif between threonine and glycine residues and anchors the protein Lo the peptidoglycan of the ceil wail of gram- posi rive bacteria.
  • Sdr proteins are thought to interact with host molecules. Known Sdr proteins include CIfA (SdrA), CIfB (SdrB), SdrC, SdrD and SdrE of S. aureus, SdrF, SdrG and SdrH of S. epidermidis, Sdrl of S. saprophytics, SdrX of S. capitis, and SdrY and SdrZ of S. caprae.
  • a preferred antibody or functional part thereof or immunoglobulin chain or functional equivalent according to the invention specifically binds S. aureus, S. epidermidis, S. sapropkyiicus, S. capitis, and S. caprae. It is preferred that said antibody, immunoglobulin chain or functional equivalent or part thereof binds to CIfA (SdrA), CIfB (SdrB), SdrC, SdrD and SdrE of S. aureus, SdrF, SdrG and SdrH of S. epidermidis, Sdrl of S. ⁇ aprophyiicus, SdrX of ⁇ S, capitis, and SdrY and SdrZ of S.
  • the epitope of the antibody, immunoglobulin chain or functional equivalent or part thereof according to the invention comprises an SD repeat-dependent epitope in Sdr proteins, for instance SD repeat-dependent epitopes as present in S. aureus CIfA, CIfB, SdrC, SdrD and SdrE.
  • An SD repeat- dependent epitope is herein defined as an epitope recognized by antibody Fl, which epitope require the presence of at least part of an SD repeat region as present in, but not limited to, S. aureus CIfA, CIfB, SdrC, SdrD and SdrE and S. epidermidis SdrF, SdrG and SdrH.
  • said epitope may comprise at least part of a molecule that binds to, or is associated with an Sdr protein.
  • examples of such molecules include, but are not limited to, amino acids, peptides, proteins, sugars and sugar residues.
  • said epitope comprises modifications of the SD repeat region. Said modifications comprise, for example, but are not limited to, glycosylation, amidation and/or phosphorylation. It will be clear to a skilled person that combination of these two embodiments is also possible.
  • the invention provides an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention capable of binding an SD repeat- dependent epitope. Also provided is an antibody or functional part or immunoglobulin chain or functional equivalent capable of binding to S. aureus CIfA, CIfB, SdrC, SdrD and SdrE. Further provided is an antibody or functional part or immunoglobulin chain or functional equivalent which is capable of competing with an antibody or functional part or immunoglobulin chain or functional equivalent according to the present invention for binding to a Staphylococcus species, preferably S. aureus and/or S. epidermidis and/or >S. saprc ⁇ hyiicus and/or ⁇ S. capitis and/or S.
  • Staphylococcus species preferably S. aureus and/or S. epidermidis and/or >S. saprc ⁇ hyiicus and/or ⁇ S. capitis and/or S.
  • caprae more preferably MRSA.
  • a disadvantage of antibodies is that their stability may be reduced, for example under harsh conditions. For instance deamidation, the removal of a functional amide group, may occur. Deamidation is a protein degradation pathway that may affect the biological functions of proteins, and which occurs mainly at asparagine residues, and to a lower extent at glutamine residues. In one embodiment, therefore, deamidation of an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is prevented by replacing an asparagine or glutamine by another amino acid. An asparagine is preferably replaced by an amino acid other than glutamine, because deamidation may also occur at a glutamine residue.
  • Replacement of an asparagine preferably does not substantially affect binding affinity of an antibody according to the invention to an antigen.
  • deamidation of an asparagine at position 53 of the heavy chain is prevented by replacing said asparagine by another amino acid.
  • the stability of an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is preferably increased.
  • replacing an asparagine at said position does not substantially affect the binding affinity for an antigen of an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention.
  • An asparagine at position 53 of the heavy chain is preferably replaced by an amino acid other than glutamine, more preferably an asparagine at said position is replaced by serine.
  • an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention, wherein an asparagine, preferably an asparagine at position 53 of the heavy chain, is replaced by another amino acid, preferably serine.
  • an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is coupled to another moiety to form antibody-drug conjugates.
  • An antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is for instance coupled to a cytotoxic agent, such as an antibiotic.
  • cytotoxic agent refers to a substance that reduces or blocks the function, or growth, of bacteria and/or causes destruction of bacteria.
  • Said other moiety for example a cytotoxic agent, is preferably coupled to said antibody or functional part thereof through a thiol group. Therefore, preferably one or more cysteines are incorporated into said antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof.
  • Cysteines contain a thiol group and therefore, incorporation of one or more cysteines into, or replacement of one or more amino acids by one or more cysteines of an antibody or functional part thereof according to the invention enable coupling thereof to another moiety.
  • Said one or more cysteines are preferably introduced into an antibody of functional equivalent thereof according to the invention at a position where it does not influence folding of said antibody or functional equivalent, and does not alter antigen binding or effector function.
  • the invention therefore provides an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention wherein at least one amino acid other than cysteine has been replaced by a cysteine.
  • at least two amino acids other than cysteine have been replaced by cysteine.
  • said at least one amino acid other than cysteine is valine at light chain position 15, and/or alanine at light chain position 144, and/or serine at light chain position 168, and/or valine at light chain position 205 and/or valine at light chain position 110, and/or alanine at heavy chain position 84, and/or alanine at heavy chain position 114, and/or alanine at heavy chain position 168, and/or serine at heavy chain position 172, more preferably valine at light chain position 205 and/or valine at light chain position 110, and/or alanine at heavy chain position 114 (numbering according to Kabat, 1991).
  • one or more other amino acids of the heavy and/or light chain can be replaced by cysteine if the replacement does not influence folding of said antibody or functional equivalent, and does not alter antigen binding or effector function.
  • An antibody or functional part or immunoglobulin chain or functional equivalent according to the invention preferably comprises a variable heavy chain sequence and/or a variable light chain sequence which is at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, most preferably at least 95% identical to a heavy chain sequence and/or the light chain sequence as depicted in Figure 1, or a light chain sequence as depicted in Figure 1 in which the isoleucine in CDR3 is altered to a methionine.
  • An antibody or functional part or immunoglobulin chain or functional equivalent according to the invention preferably comprises a heavy chain as well as a light chain which resemble the heavy and light chain of Fl.
  • an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof comprising a heavy chain sequence and a light chain sequence which are at least 70%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, most preferably at least 95% identical to the heavy chain sequence and the light chain sequence as depicted in Figure 1, or a light chain sequence as depicted in Figure 1 in which the isoleucine in CDR3 is altered to a methionine.
  • an antibody or functional part which has a heavy chain sequence as depicted in Figure 1 and a light chain sequence as depicted in Figure 1 or a light chain sequence as depicted in Figure 1 in which the isoleucine in CDR3 is altered to a methionine.
  • immunoglobulin chain or functional equivalent thereof comprising a heavy chain sequence consisting of the heavy chain sequence as depicted in Figure 1, and/or comprising a light chain sequence consisting of the light chain sequence as depicted in Figure 1 or a light chain sequence as depicted in Figure 1 in which the isoleucine in
  • CDR3 is altered to a methionine.
  • a shortened heavy chain or light chain sequence while maintaining a binding property of interest.
  • a shortened heavy chain or light chain is generated which has a shorter constant region, as compared to the original heavy or light chain.
  • the variable domain is preferably maintained. For instance, a Fab fragment or F(ab')2 fragment or a single domain antibody or a single chain antibody or a nanobody or an unibody or a scFv fragment based on a heavy chain sequence or light chain sequence depicted in Figure 1 is produced.
  • a functional part of an antibody comprising at least a functional part of a sequence as depicted in Figure 1, or a light chain sequence as depicted in Figure 1 in which the isoleucine in CDR3 is altered to a methionine, is therefore also provided.
  • Said functional part has a length of at least 20 amino acids and comprises at least one sequence selected from the group consisting of a sequence which is at least 70% identical to the heavy chain CDRl sequence depicted in Figure 1 and a sequence which is at least 70% identical to the heavy chain CDR2 sequence depicted in Figure 1 and a sequence which is at least 70% identical to the heavy chain CDR3 sequence depicted in Figure 1 and a sequence which is at least 70% identical to the light chain CDRl sequence depicted in Figure 1 and a sequence which is at least 70% identical to the light chain CDR2 sequence depicted in Figure 1 and a sequence which is at least 70% identical to the light chain CDR3 sequence depicted in Figure 1, or a light chain CDR3 sequence as depicted in Figure 1 in which the isoleucine is altered to a methionine.
  • the invention further provides an isolated, synthetic or recombinant nucleic acid sequence or a functional equivalent thereof with a length of at least 15 nucleotides, preferably at least 30 nucleot
  • nucleotides are preferably at least 75 nucleotides, encoding a binding compound according to the invention.
  • Such nucleic acid is for instance isolated from a B-cell which is capable of producing an antibody according to the invention.
  • a preferred embodiment provides a nucleic acid sequence comprising a sequence which has at least 70% sequence identity to at least 15 nucleotides of a nucleic acid sequence as depicted in Figure 1.
  • a nucleic acid sequence according to the invention preferably comprises a sequence which has at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, most preferably at least 95% sequence identity to at least 15 nucleotides of a nucleic acid sequence as depicted in Figure 1.
  • said nucleic acid sequence as depicted in Figure 1 comprises at least one CDR encoding sequence.
  • One preferred embodiment provides an isolated, synthetic or recombinant nucleic acid sequence with a length of at least 15 nucleotides, or a functional equivalent thereof, encoding at least one CDR sequence of an antibody or
  • Said nucleic acid sequence preferably encodes at least one CDR sequence which has at least 70% sequence identity to a CDR region of antibody Fl.
  • Nucleic acid sequences encoding Fl CDR regions are depicted in Figure 1. Further provided is therefore an isolated, synthetic or recombinant nucleic acid sequence, or a functional equivalent thereof, comprising a sequence which has at least 70% sequence identity to a sequence selected from the group consisting of cgctttgccatgagc (SEQ ID NO:12),
  • Said nucleic acid sequence or functional equivalent preferably comprises a sequence which has at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90% sequence identity to any of the above mentioned sequences. Further provided is a nucleic acid sequence or functional equivalent thereof comprising a sequence which has at least 70% sequence identity to at least part of a nucleotide sequence as depicted in Figure 1, said part having at least 15 nucleotides and encoding at least one CDR region.
  • a nucleic acid sequence or functional equivalent thereof preferably encodes a region which has at least 70% sequence identity to an Fl CDR region, an Fl heavy chain and/or an Fl light chain.
  • One embodiment thus provides an isolated, synthetic or recombinant nucleic acid sequence, or a functional equivalent thereof, comprising a sequence encoding an amino acid sequence which has at least 70% sequence identity to the sequence RFAMS (SEQ ID NO:1), and/or at least 70% sequence identity to the sequence SINNGNNPYYARSVQY (SEQ ID NO:2), and/or at least 70% sequence identity to the sequence DHPSSGWPTFDS (SEQ ID NO:3), and/or at least 70% sequence identity to the sequence RASENVGD WLA (SEQ ID NO:4), and/or at least 70% sequence identity to the sequence KTSILES (SEQ ID NO:5), and/or at least 70% sequence identity to the sequence QHYXRFPYT, wherein X is I or M (SEQ ID NO:6), and/or at least 70% sequence identity to the sequence
  • nucleic acid sequences or functional equivalents thereof encoding variants of the Fl antibody according to the invention are, for example, nucleic acid sequences encoding a heavy chain sequence comprising the sequence
  • said asparagine is replaced by a serine.
  • % sequence identity is defined herein as the percentage of residues in a candidate amino acid of nucleic acid sequence that is identical with the residues in a reference sequence after aligning the two sequences and introducing gaps, if necessary, to achieve the maximum percent identity. Methods and computer programs for the alignment are well known in the art.
  • a nucleic acid molecule or nucleic acid sequence of the invention preferably comprises a chain of nucleotides, more preferably DNA and/or RNA.
  • a nucleic acid molecule or nucleic acid sequence of the invention comprises other kinds of nucleic acid structures such as for instance a DNA/RNA helix, peptide nucleic acid (PNA), locked nucleic acid (LNA) and/or a ribozyme.
  • PNA peptide nucleic acid
  • LNA locked nucleic acid
  • ribozyme a nucleic acid sequence
  • nucleic acid sequence also encompasses a chain comprising non-natural nucleotides, modified nucleotides and/or non-nucleotide building blocks which exhibit the same function as natural nucleotides.
  • a nucleic acid sequence according to the present invention is particularly useful for generating binding compounds which are specific for S. aureus and/or S. epidermidis. This is for instance done by introducing such nucleic acid sequence into a cell so that the cell's nucleic acid translation machinery will produce the encoded binding compound.
  • genes encoding a heavy and/or light chain according to the invention are expressed in so called producer cells, such as for instance cells of a Chinese hamster ovary (CHO), NSO (a mouse myeloma) or 293(T) cell line, some of which are adapted to commercial antibody production. Proliferation of said producer cells results in a producer cell line capable of producing antibodies or functional parts thereof according to the present invention.
  • said producer cell line is suitable for producing compounds for use in humans.
  • said producer cell line is preferably free of pathogenic agents such as pathogenic micro-organisms.
  • binding compounds consisting of human sequences are generated using a nucleic acid sequence according to the invention.
  • An isolated or recombinant antibody producing cell capable of producing an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention is therefore also provided, as well as a method for producing an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention, comprising providing a cell with a nucleic acid sequence or functional equivalent according to the invention and allowing said cell to translate said nucleic acid sequence or functional equivalent according to the invention, thereby producing said antibody or functional part or immunoglobulin chain or functional equivalent according to the invention.
  • An antibody producing cell is defined herein as a cell which is capable of producing and/or secreting an antibody or a functional part thereof, and/or which is capable of developing into a cell which is capable of producing and/or secreting antibody or a functional part thereof.
  • An antibody producing cell according to the invention is preferably a producer cell which is adapted to commercial antibody production.
  • said producer cell is suitable for producing compounds for use in humans.
  • a method according to the invention preferably further comprises a step of harvesting, purifying and/or isolating said antibody or functional part or
  • binding compounds according to the invention are preferably used in diagnosis of Staphylococcus infection, isolation or detection of Staphylococcus bacteria, distinguishing between Staphylococcus species and other gram-positive bacteria and human therapy, optionally after additional purification, isolation and/or other processing steps.
  • an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the present invention is particularly suitable for diagnostic uses.
  • a sample such as a tissue or blood sample
  • a Staphylococcus bacteria preferably S. aureus and/or S. epidermidis, more preferably MRSA.
  • said sample can be mixed with an antibody or immunoglobulin chain or functional equivalent or part thereof according to the invention.
  • Said antibody, immunoglobulin chain or functional equivalent or part will specifically bind to Staphylococcus bacteria, preferably S. aureus and/or S. epidermidis.
  • Bacteria bound to an antibody, immunoglobulin chain or functional equivalent or part can be isolated from the sample using any method known in the art, for example, but not limited to, isolation using magnetic beads, streptavidin-coated beads, or isolation through the use of secondary antibodies immobilized on a column. After washing of the bound bacteria and antibody, immunoglobulin chain or functional equivalent or part thereof, bacteria can be eluted from said antibody, immunoglobulin chain or functional equivalent or part by any method known in the art. For instance, binding between bacteria and antibody, immunoglobulin chain or functional equivalent or part can be disrupted by increasing the concentration of salts and/or reducing or increasing pH, and/or by addition of excess epitope.
  • Staphylococcus bacteria preferably S. aureus and/or S.
  • epidermidis may be used for various applications. For instance, infection with several different gram-positive bacteria may result in overlapping symptoms in an individual. In such cases, it can be difficult to discriminate between S. aureus and/or S.
  • S. aureus and/or S. epidermidis can then be used to detect the presence of S. aureus and/or S. epidermidis, or for distinguishing between S. aureus and/or S. epidermidis and other bacteria.
  • Isolation of bacteria from a sample of an individual suspected of suffering from an infection with S. aureus and/or S. epidermidis or from any other source, such as a bacterial culture, can facilitate detection of said Staphylococcus bacteria, because isolation results in an increased concentration and/or a higher purity of said Staphylococcus bacteria.
  • Isolation of Staphylococcus species preferably S. aureus and/or S. epidermidis, more preferably MRSA
  • S. aureus and/or S. epidermidis can for instance further be used to identify the specific S. aureus and/or S. epidermidis strain, preferably the MRSA strain in a sample.
  • Identification of said strain can for instance be performed by determining the sequence of the bacterial DNA. In such case it is preferred to first obtain an isolated S. aureus and/or S. epidermidis.
  • an antibody, immunoglobulin chain or functional equivalent or part thereof according to the present invention is labeled in order to be able to detect said antibody, immunoglobulin chain, or functional equivalent or part, for instance, but not limited to, fluorescently labeled, or radioactively labeled.
  • an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is detected using a labeled secondary antibody which is directed against said antibody, immunoglobulin chain or functional equivalent or part thereof according to the invention. If binding of said antibody, immunoglobulin chain or functional equivalent or part thereof is detected, S. aureus and/or S. epidermidis is present.
  • an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof for diagnosis of a Staphylococcus infection, preferably S. aureus infection, more preferably MRSA infection, for detecting S. aureus and/or S. epidermidis, preferably MRSA, and for distinguishing between S. aureus and/or S. epidermidis, preferably MRSA and other gram-positive bacteria.
  • an antibody or functional part thereof or an immunoglobulin chain or functional equivalent thereof according to the invention for use in the diagnosis of a Staphylococcus infection, preferably S. aureus infection, more preferably MRSA infection.
  • S. aureus and/or S. epidermidis bacteria from a solution using an antibody or functional part or an immunoglobulin chain or functional equivalent thereof according to the invention.
  • Said method preferably comprises providing a sample of an individual suspected of suffering from an infection with S. aureus and/or S. epidermidis, preferably MRSA, or from any other source, such as a bacterial culture, adding an antibody or functional part or an immunoglobulin chain or functional equivalent thereof according to the invention to said sample, allowing binding of said antibody or functional part or an
  • immunoglobulin chain or functional equivalent thereof according to the invention to S. aureus and/or S. epidermidis bacteria, when present, and isolating S. aureus and/or S. epidermidis bacteria bound to an antibody or functional part or an immunoglobulin chain or functional equivalent thereof according to the invention from said sample.
  • Gram-positive bacteria-specific binding compounds according to the invention and nucleic acid sequences coding therefore have been provided, including human binding compounds, improved therapeutic applications have become available.
  • Gram-positive bacteria such as S. aureus and/or S. epidermidis are counteracted by binding compounds according to the invention.
  • a binding compound according to the invention is therefore particularly suitable for use as a medicine or prophylactic agent.
  • binding compounds are used which consist of human sequences, or which have at most 5% of non-human sequences, in order to reduce the chance of adverse side effects when human individuals are treated.
  • An antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to the invention for use as a medicament and/or prophylactic agent is therefore also herewith provided.
  • nucleic acid or functional equivalent according to the invention When a nucleic acid or functional equivalent according to the invention is administered, it will be translated in situ into a binding compound according to the invention.
  • said antibody comprises antibody Fl, or a functional part thereof.
  • Said medicament or prophylactic agent is preferably used for counteracting or at least in part preventing an infection by S. aureus and/or S.
  • epidermidis or for counteracting or at least in part preventing adverse effects of an infection by S. aureus and/or S. epidermidis.
  • an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to the invention for use as a medicament and/or prophylactic agent for at least in part treating and/or preventing a condition related to S. aureus and/or S. epidermidis.
  • Non-limiting examples of such conditions are skin infections, pimples, impetigo, boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome, abscesses, pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome and septicemia.
  • S. aureus infection is counteracted or at least in part prevented.
  • an MRSA-related condition is counteracted, diminished and/or at least in part prevented.
  • a use of an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to the invention for the preparation of a medicament and/or prophylactic agent for at least in part treating and/or preventing S. aureus and/or S. epidermidis is therefore also provided, as well as a method for at least in part treating or preventing a condition related to S. aureus and/or S.
  • the method comprising administering to an individual in need thereof a therapeutically effective amount of an antibody or functional part or an immunoglobulin chain or functional equivalent according to the invention, preferably after said individual has been diagnosed to be infected by S. aureus and/or S.
  • Said condition preferably comprises at least one of the S. aureus-related conditions listed above, most preferably an MRSA-related condition.
  • Said antibody preferably comprises antibody Fl, or a functional part thereof.
  • a binding compound according to the invention is preferably administered to an individual before an infection has taken place.
  • a binding compound according to the invention is administered when an individual is already infected.
  • Said binding compound is preferably administered to individuals with an increased risk of complications, such as for instance hospitalized individuals and/or individuals with compromised immunity. Also elderly people have an increased risk of bacterial conditions.
  • Binding compounds according to the invention are preferably administered via one or more injections. Dose ranges of binding compounds according to the invention to be used in the therapeutic applications as described herein before are designed on the basis of rising dose studies in the clinic in clinical trials for which rigorous protocol requirements exist. Typical doses are between 0.1 and 10 mg per kg body weight.
  • binding compounds according to the invention are typically combined with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • suitable carriers for instance comprise keyhole limpet haemocyanin (KLH), serum albumin (e.g. BSA or RSA) and ovalbumin.
  • said suitable carrier comprises a solution like for example saline.
  • a nucleic acid encoding a binding compound according to the invention is used. As already described, upon administration of such nucleic acid, binding compounds are produced by the host's machinery. Produced binding compounds are capable of preventing and/or counteracting Gram-positive bacterial infection and/or the adverse effects of such infection.
  • a nucleic acid sequence or functional equivalent according to the invention for use as a medicament and/or prophylactic agent is therefore also herewith provided. Said nucleic acid is preferably used for counteracting S.
  • aureus and/or S. epidermidis more preferably S. aureus, most preferably MRSA.
  • a nucleic acid sequence or functional equivalent according to the invention for the preparation of a medicament and/or prophylactic agent for at least in part treating and/or preventing a Gram-positive bacterium-related condition.
  • Said Gram-positive bacterium-related condition preferably comprises an infection by S. aureus or S. epidermidis, more preferably an S. aureus infection, most preferably an MRSA infection.
  • composition comprising an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to the invention and a pharmaceutical acceptable carrier, diluent or excipient.
  • Said pharmaceutical composition is preferably suitable for human use.
  • B-cells were obtained from fresh blood of adults by Ficoll separation and
  • CD27 + IgD IgA on a FACSaria (Becton Dickinson). The use of these tissues was approved by the medical ethical committees of the institution and was contingent on informed consent. Donors were selected based on carrying hospital acquired MRSA strains with genotype cluster 109 and 16.
  • mice L cell fibroblasts stably expressing CD40L (CD40L-L cells, 10 5 cells/ml) and recombinant mouse IL-21 (25ng/ml, R&D systems).
  • rhIL-4 R&D was used at
  • BCL6 retroviral construct has been described before (Shvarts A. et al. Genes Dev 16, 681-686 (2002)).
  • cDNA encoding human Bcl-xL was kindly provided by Dr. Stanley Korsmeyer.
  • BCL6 and Bcl-xL were separately cloned into a BCL6-NGFR and a BcIxL- GFP construct.
  • These constructs were transfected into the LZRS retroviral packaging cells, phoenix as described before (Jaleco A. C. et al. Blood 94, 2637-2646 (1999);
  • ELISA plates were coated with anti-human IgG (Jackson ImmunoResearch Laboratories) at 5 ⁇ g/ml in PBS for lhr at 37°C or o/n at 4°C and washed in ELISA wash buffer (PBS, 0.5% Tween-20). 4% milk in PBS was used as blocking agent, before serial dilution of cell culture supernatants and an enzyme-conjugated detection antibody was added (dilution 1:2500 for HRP-conjugated anti-IgG (Jackson)). TMB substrate/stop solution (Biosource) was used for
  • subtilis, S. faecalis and S. pyogenes (Sigma) was added to ELISA plates coated with polyclonal IgG purified mouse anti-LTA (1/200 stock 1 mg ml ⁇ QED Bioscience), before secondary antibodies were added.
  • LTA preparations were coated at 1 ⁇ g ml x before rFl (10 ⁇ g ml x ) or control antibodies (1:5 dilution of hybridoma supernatant) were added and further detected with conjugated anti-human or mouse antibodies.
  • the panel of purified LTA preparations included: B. subtilis, S. aureus, L. lactis, L. gar ⁇ ieae, B. bifidum, M. luteus, L. casei, L. mesenteroides, B. licheniformis, L. welshimeri, E. hirae, L. raffinolactis, S. mutans, S. pneumoniae.
  • Several variants contain or lack alanine residues and/or lipid anchors (not depicted here). Binding of the Fl antibody to bacterial cultures
  • Newman S. aureus and the S. pneumoniae strain were used. Newman was cultured in TSH 50 ml O/N, then 1 ml was resuspendend in 100 ml for 2 to 2.5 hrs till OD:1 and bacteria were collected. S. pneumoniae was cultured in Todd Hewitt medium mixed with yeast medium. Before, bacteria were incubated with Fl antibody, a control IgG (D25, a human anti-RSV antibody) or only with the secondary antibody (IgG-PE only), cells were pretreated with 100% total mouse serum to prevent background staining. After washing the secondary antibody was added (IgG-PE). Antibody incubations were performed for 20 min on ice. Fl sequence determination and expression cloning
  • aureus-specific IgG antibodies in these ELISAs the coating was cell lysates of two S. aureus strains, SHlOOO and Newman). Mini-cultures that were screened positive in both the SHlOOO as well as the Newman S. aureus were seeded in new mini-cultures at a density of 10 cells/well. Again, supernatant of these mini-cultures was collected and screened in the SHlOOO and Newman ELISAs. Clones that were screened positive in both ELISAs were seeded into monoclonal cultures (i.e. 1 cell/well). After testing the supernatant of these monoclonal cultures, one clone (named Fl) was found to produce S. aureus specific monoclonal IgG antibodies.
  • Fl monoclonal cultures
  • Another control was an anti-influenza virus antibody that only detected influenza H3 protein.
  • the recombinant produced Fl antibody binds to LTA preparations from multiple sources
  • the rFl antibody was tested on purified LTA preparations from several bacteria. As shown in Figure 2A, the rFl antibody binds well to commercial LTA samples obtained from S. aureus and B. subtilis, and a bit less profoundly to LTA samples from S. faecalis and S. pyogenes. The rFl antibody did not bind to an LTA sample from S. pneumoniae (data not shown). In addition rFl recognized highly purified LTA samples from B. subtilis, B. licheniformis and two isolates of S. aureus (Figure 2b). rFl did not bind to LTA preparations from S. mutans (Fig. 2b) or from L. lactis, L. gar ⁇ ieae, B. bifidum, M. luteus, L. casei,
  • Recombinant Fl antibody binds to living S. aureus bacteria
  • Example 2 METHODS Bacterial strains and culture.
  • Enterococcus faecalis, and Streptococcus pyogenes were obtained from Ward's Natural Science; Listeria monocytogenes was from ATCC.
  • Bacteria were grown on tryptic soy agar (TSA) plates supplemented with 5% sheep blood for 18 h at 37 0 C.
  • TSA tryptic soy agar
  • bacteria were harvested from TSA plates or TSB cultures, and washed with Hank's Buffered Salt Solution (HBSS) without phenol red supplemented with 0.1% BSA (IgG free; Sigma) and 10 mM Hepes, pH 7.4 (HB buffer), by centrifugation at 1700 x g for 20 min. Bacterial concentrations were estimated by reading optical density at 630 nm. Bacterial suspensions of 2OxIO 8 CFU/mL in HB buffer were mixed with equal volumes of 300 ⁇ g/mL of rabbit IgG (Sigma), and incubated for 1 h at room temperature (RT) to block nonspecific IgG binding.
  • HBSS Hank's Buffered Salt Solution
  • rabbit IgG anti-S. aureus (Abeam) was added to a concentration of 20 ⁇ g/mL. After incubation for 15 min at RT, cells were washed twice with HB buffer, and resuspended in a mixture of anti-human IgG and anti-rabbit IgG secondary antibodies, each labeled with a different fluorochrome (Jackson Immunoresearch). After two washes with PBS, cells were resuspended in PBS with 2%
  • RESULTS rFl binds strongly to 14 S. aureus strains and S. ⁇ pid ⁇ rmidis Seven Methicillin-resistant S. aureus (MRSA) strains, six methicillin- sensitive S. aureus (MSSA) strains, one vancomycin intermediate sensitive S. aureus (VISA) strain, S. epidermidis and several other gram-positive species were tested for binding to rFl antibody.
  • MRSA Methicillin-resistant S. aureus
  • MSSA methicillin- sensitive S. aureus
  • VISA vancomycin intermediate sensitive S. aureus
  • S. epidermidis S. epidermidis
  • rFl strongly binds to all 14 S. aureus strains (figure 4A) and to S. epidermidis (figure 4B), but not to the other tested gram- positive species (figure 4B).
  • rFl binds to MRSA from different growth stages and from in vivo infection
  • Wood46 S. aureus strain (Biodesign/ Meridian Life Sciences, Maine) was split into two parts and immunoprecipitated with 1 ug/ml of rFl or isotype control human antibody. Antibodies were captured with Protein A/G Ultralink Resin (Pierce). The samples were then treated with 5OmM dithiothreitol, 1OmM 2-Iodoacetamide and run on an 8% Tris-glycine gel and subsequently Western blotted with rFl.
  • a cell wall preparation of a 20 ml overnight culture of USA300 S. aureus strain was prepared by treatment of the culture (40 mg cell pellet/ml) with 100mg/ml of lysostaphin in 30% raffinose buffer at 37°C for 30 minutes. The entire cell wall prep was filtered, diluted up to 10 ml with NP40 Lysis buffer and incubated twice with anti-Flag M2 Agarose (Sigma) to deplete as much protein-A from the cell wall prep as possible. Final cell wall preparation was split into two parts and
  • Antibodies were captured with Protein A/G Ultralink Resin (Pierce). The samples were then treated with 5OmM dithiothreitol, 1OmM 2-Iodoacetamide and run on an 8% Tris-glycine gel and subsequently silver stained or Western blotted with rFl.
  • Lysates from a 20 ml overnight culture of Staphylococcus epidermidis was prepared by bead beating in NP40 Lysis Buffer.
  • the resulting lysate preparation was diluted to 10 ml with NP40 Lysis Buffer, split into two parts and immunoprecipitated with 1 ug/ml of rFl or control antibody.
  • Antibodies were captured with Protein A/G Ultralink Resin (Pierce).
  • the samples were then treated with 5OmM dithiothreitol, 1OmM 2-Iodoacetamide and run on an 8% Tris-glycine gel and subsequently silver stained or Western blotted with rFl.
  • C.aureus expression of His -tagged CIfA The Clumping factor- A (CIfA) gene was PCR amplified from the sequence encoding the signal sequence to the sequence encoding the glycine in the LPXTG motif from USA300 genomic DNA. A c-terminal His Tag was engineered at the end of the LPXTG motif and ligated into the pTet S.aureus expression vector (pSASlO from Genentech). The resulting construct was then electroporated into S. aureus WT RN4220.
  • pSASlO pTet S.aureus expression vector
  • a 20 ml culture of either the electroporated RN4220 or RN4220 empty (not carrying a pTet expression vector) was inoculated from an overnight culture (starting OD ⁇ oo of 0.15), grown for 1 hr in trypticase soy broth (TSB) and then induced protein expression for 2 hrs with anhydrotetracycline (200 ng/ml). At the end of the induction period, the S.
  • aureus culture was pre-lysed with lysostaphin (50 ug/ml) and then further lysed by bead beating in lysis buffer (150 mM NaCl, 20 mM Tris pH 7.5, 1% triton-X, and Roche protease inhibitor EDTA-free tablets). Cleared lysates were then incubated with NiNta resin (Qiagen) in the presence of 10 mM Imidazole for 1 hr at 4°C to pull-down the recombinant CIfA protein.
  • lysis buffer 150 mM NaCl, 20 mM Tris pH 7.5, 1% triton-X, and Roche protease inhibitor EDTA-free tablets.
  • Cleared lysates were then incubated with NiNta resin (Qiagen) in the presence of 10 mM Imidazole for 1 hr at 4°C to pull-down the recombinant CIfA protein.
  • S. aureus cell surface SDR proteins CIfA, CIfB, SdrC, SdrD, SdrE in E.coli The CIfA, CIfB, SdrC, SdrD and SdrE genes were PCR amplified from the sequence encoding the mature start of the protein to the sequence encoding the glycine in the LPXTG motif from USA300 genomic DNA and ligated in- frame with an N-terminal Unizyme tag into the ST239 Vector (Genentech). The constructs were transformed into E.coli 58F3 (Genentech), induced for protein expression and subsequently purified.
  • NiNta capture of NT Unizyme tagged SDR proteins 500ug of purified N- terminal Unizyme tagged SDR proteins (CIfA, CIfB, SdrC, SdrD, SdrE) were diluted in PBS containing protease inhibitors (EDTA-free) and incubated with NiNta resin (Qiagen) for 1.5 hr at 4°C. NiNta resin with the captured Unizyme tagged SDR protein was then washed once with wash buffer (50 mM NaEbPCU, 30OmM NaCl; pH 8.0).
  • wash buffer 50 mM NaEbPCU, 30OmM NaCl; pH 8.0.
  • MBP-SD Constructs The maltose binding protein (MBP) gene was PCR amplified from the pMAL-c5x vector (New England BioLabs [NEB], Ipswich, MA, USA) from the sequence encoding the start of the mature protein until the sequence encoding the end of the Factor Xa cleavage site.
  • the varying lengths of c-terminal His tagged SD (SD, SDS, DSD, SDSD, SDSDS, SDSDSD) were synthesized as single stranded oligonucleotides and annealed together to make double stranded dna.
  • the Sdr region of the CIfA gene was PCR amplified from the sequence encoding the beginning (560D) of the Sdr region and included up to either the sequence encoding 618A or 709S of the SD region followed by the dna sequence coding for a His Tag from the respective plasmids pTet.ClfA.SD618A or pTet.ClfA.SD709S (Genentech).
  • the sequence encoding the A domain of the CIfA gene from the beginning of the mature protein until the sequence encoding the end of the A domain (538G) followed by the sequence coding for a His Tag was PCR amplified from the plasmid pTet.ClfA.Adom.538G (Genentech).
  • the MBP insert along with one of the various SD inserts or CIfA A domain were ligated into the pTet S. aureus expression vector (pSASlO from Genentech).
  • the resulting constructs were then electroporated into the S. aureus RN4220 ⁇ sortase (sortase deletion mutant strain in the RN4220 background).
  • a 20 ml culture of either the electroporated RN4220 ⁇ sortase or RN4220 ⁇ sortase empty (not carrying a pTet expression vector) was inoculated from an overnight culture (starting OD ⁇ oo of 0.15), grown for 1 hr in trypticase soy broth (TSB) supplemented with glucose (2 g/L) and then induced for protein expression for 2 hrs with anhydrotetracycline (200 ng/ml). At the end of the induction period, the S.
  • TTB trypticase soy broth
  • aureus culture was resuspended in Column Buffer (150 mM NaCl, 2OmM Tris pH 7.5 and Roche protease inhibitor EDTA-free tablets) and lysed with 200 ug/ml lysostaphin in the presence of 250 units of Benzonase Nuclease (Novagen) at 37°C for 30 minutes.
  • the lysates were cleared of debris by spinning down at maximum speed in a microcentrifuge for 10 minutes at 4°C.
  • the cleared lysates were then incubated with amylose resin (NEB) along with a final EDTA concentration of ImM for 1.5 hrs at 4°C to capture the expressed MBP-SD proteins.
  • NEB amylose resin
  • RESULTS rFl reacts to a unique family of SDR (Ser-Asp-repeat) proteins in S. aureus and S. ⁇ pid ⁇ rmidis
  • WTA cell wall lysate
  • rFl binds to several components of the commercial teichoic acid preparation (figure 6A, left panel) and of the cell wall lysate of S. aureus (figure 6B, left panel). Using mass spectrometry these components of the WTA preparation and cell wall lysate were identified as CIfA (SdrA), CIfB (SdrB), SdrC, SdrD and SdrE (figure 6A, right panel and figure 6B, right panel)
  • FIG. 6C shows binding of rFl to several components of a cell wall lysate of S. epidermidis. These components were not identified with a control antibody. Using mass spectrometry these cell wall components were identified as SdrF, SdrG and SdrH (figure 6C right panel).
  • rFl antibody binds to CIfA Sdr regions consisting of the CIfA 560D-618S and CIfA 560D-709S (figure 8) expressed in S. aureus. rFl does not bind to the A-domain of CIfA or to small peptide sequences consisting of up to three SD repeats.
  • Phusion DNA polymerase, restriction enzymes EcoRV, Kpnl, PvuII, Apal, Agel, and Ahdl, T4 DNA ligase were purchased from New England BioLabs, Ipswich, MA, USA.
  • Pfu DNA polymerase, Quick change II Site-Directed Mutagenesis Kit were purchased from Stratagene/Agilent Technologies, Santa Clara, California, USA.
  • 2% agarose gel was purchased from Invitrogen, Carlsbad, California, USA.
  • pRK vectors pRK.LPG3.HuKappa and pRK.LPG4.HumanHC were obtained from
  • variable domains of heavy and light chains of rFl Mab from the pCPEO vectors were placed into the pRK mammalian expression vectors.
  • Polymerase chain reaction (PCR) was performed in a total volume of 50 ⁇ l using Pfu DNA polymerase according to standard PCR procedures.
  • VH was amplified with the primers YiHCF) 5'- ATG GCT GAG GTG CAG CTG GTG GAG TCT G-3' (SEQ ID NO:18) and YiH CR2 5'- GAA CAC GCT GGG GCC CTT GGT GCT GGC ACT CGA GAC TGT GAC CAG GGT GCC AGG T*CC CCA G-3' (SEQ ID NO:19) (the restriction sites of PvuII and Apal are underlined and the * indicates the single nucleotide G to T change to eliminate the internal Apal site) and VL was amplified with the primers YiLCF 5'-CGG CTC
  • VH and VL were individually ligated into pRK vector fragments of pRK/Pvull, Apal for Heavy chain and pRK/EcoRV, Kpnl for light chain using T 4 DNA ligase.
  • the DNA plasmids were confirmed by restriction enzyme digestion patterns, i.e. ⁇ FIVH released ⁇ 300 bp and 5.8 kb bands by Agel, whereas ⁇ FIVL shown 2.3 and 3.1 kb bands by Ahdl on 2% agarose gel.
  • the rFl pRK plasmids underwent a series of site- directed mutagenesis to stabilize the rFl Mab by N (AAC) 53S (AGC) in heavy chain CDR2 with using FHV 5'- GGT GGC CAG CAT CAA CAG CGG CAA CAA CCC CTA CTA CG-3' (SEQ ID NO: 1
  • Site-directed mutagenesis was performed to stabilize the rFl Mab by N (AAC, (SEQ ID NO:25)) to 53S (AGC, (SEQ ID NO:26)) substitution in heavy chain CDR2. Sequencing of the mutagenesis variant confirmed an N53S mutation.
  • rFl pRK plasmids underwent a series of site-directed mutagenesis with oligos of rFlpRK.LC(205/210)VCF (468075) 5'-GGG CCT GAG CTC GCC CTG CAC AAA GAG CTT CAA CAG-3' (SEQ ID NO:27) and rFlpRK.LC(205/210)VCR
  • rFlpRK.HCN53S.Al2lCR (468465) 5'-GAT GGG CCC TTG GTG CTG CAA CTC GAG ACT GTG ACC AG-3' (SEQ ID NO:30) (Cys mutant is underlined) to make the heavy chain linkers of rFl thioMab via the Stratagene's Site-Directed method.
  • Light chain V205C and heavy chain A114C were confirmed by sequencing of the variants (figure 9). Brief description of the drawings
  • FIG. 1 Heavy chain and light chain sequences of antibody Fl
  • Figure 2 Fl antibody binds to LTA preparations from several Gram-positive bacteria, (a) LTA preparations were derived from Sigma and tested in a capture ELISA with a mouse polyclonal anti-LTA or (b) a highly purified set of LTA preparations derived from W. Fischer. D25, a human anti-RSV antibody was used as non-specific negative control and a mouse monoclonal anti-LTA antibody as a positive control.
  • FIG. 3 Recombinant Fl antibody binds to S. aureus but not to S. pneumoniae,
  • Bacteria were incubated with Fl antibody, or a control IgG (D25, a human anti-RSV antibody) or without first antibody (IgG-PE only). After washing the secondary antibody was added (IgG-PE).
  • 6 clinical isolates were tested in two separate experiments for the binding of Fl. Tested were a PVL+ strain (SA-I), 3 regular (SA-2 SA-3 and SA-4), and 2 MRSA strains (SA-5 and SA-6).
  • Figure 4 (a) Binding of rFl antibody to 14 S. aureus strains, (b) rFl antibody binds to S. epidermidis but not to Bacillus subtilis, Enterococcus faecalis, Listeria monocytogenes and Streptococcus pyogenes.
  • Figure 5 (a) rFl antibody binds to MRSA in different growth stages, Iso C: isotype control, Med: media control (b) rFl antibody binds to MRSA isolated from infected tissue.
  • rFl antibody binds to SDR proteins, (a) Immunoprecipitation (IP) of a commercial teichoic acid preparation of S. aureus (Wood 46 strain) with rFl or isotype control antibody, followed by Western blotting with rFl antibody (left) and mass spectrometry analysis of fragments from the WTA preparation bound by rFl antibody (right), (b) Immunoprecipitation (IP) of cell wall lysate of S.
  • IP Immunoprecipitation
  • Figure 8 rFl binds to SDR domains expressed by S. aureus. Constructs expressed by S. aureus and tested for binding to rFl (left), Western blots of S. aureus lysates containing the expressed constructs with anti-MBP (maltose binding protein), anti- His and rFl antibody (right).
  • MBP maltose binding protein
  • Figure 9 Sequences of heavy chain A114C (a) and light chain V205C (b) variants of antibody rFl. Numbering according to Kabat (1991), boxes: CDRs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)

Abstract

The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

Description

Title: Gram-positive bacteria specific binding compounds
The invention relates to the fields of biology, immunology and medicine.
Gram-positive microorganisms cause the majority of systemic infections. One important member of these Gram-positive pathogens is Staphylococcus aureus (S. aureus). About 20% of the population is a long-term carrier of S. aureus. S. aureus can cause a range of illnesses from minor skin infections, such as pimples, impetigo (may also be caused by Streptococcus pyogenes), boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome and abscesses, to life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, Toxic shock syndrome (TSS), and septicemia. S. aureus is capable of infecting all kinds of organs and tissues. S. aureus infections occur in immunocompetent as well as immune compromised people. About 50% of the infections in US intensive care units are caused by this pathogen. Three hundred thousand S. aureus infections per year, resulting in 12,000 deaths, are reported in the US (see also Moran et al. NEMJ 355, 666-674 (2006)).
A major problem is the increasing antibiotic resistance of S. aureus.
Methicillin-resistant S. aureus (MRSA) emerged in the 1960s. It was initially identified in health care settings. However, MRSA appears to be present among persons in the community which have not been hospitalized. Treatment of MRSA is difficult and expensive, due to the limited sensitivity of MRSA to antibiotics.
However, very few alternatives of antibiotics are available. Vancomycin is often used to treat penicillin-resistant MRSA. US patent 6,939,543 describes a murine antibody against lipoteichoic acid (LTA) which is capable of binding S. aureus. Based on this murine antibody, a recombinant chimeric mouse/human antibody was produced which contains human heavy and light chain constant domains. However, such chimeric mouse/human antibody has the disadvantage that murine sequences are present, which involves the risk of serious side effects when administered to humans.
It is an object of the present invention to provide means and methods for counteracting and/or preventing Gram-positive bacteria-related diseases. It is a further object of the invention to provide alternative and/or improved binding compounds against various Gram-positive bacteria, preferably Staphylococcus species, more preferably MRSA. It is a further object of the invention to provide human binding compounds against various Gram-positive bacteria, preferably Staphylococcus species, more preferably MRSA. The present invention provides antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof capable of specifically binding Staphylococcus species in their natural context. Therefore, they are useful for counteracting and/or preventing and/or diagnosing disorders related to the presence of Staphylococcus species. Preferably, S. aureus is counteracted. In a particularly preferred embodiment, MRSA is counteracted. Another preferred Staphylococcus species which is counteracted is Staphylococcus epidermidis.
Staphylococcus epidermidis is usually non-pathogenic, but patients with a compromised immune system are often at risk for developing an infection. Infections can be both hospital and community acquired, but they are more of a threat to hospital patients. Most susceptible to infection with S. epidermidis are intravenous drug users, newborns, elderly, and those using catheters or other artificial appliances. Infections are associated with intravascular devices (prosthetic heart valves, shunts, etc.) but also commonly occur in prosthetic joints, catheters, and large wounds.
Symptoms include fever, headache, fatigue, anorexia and dyspnea.
In a preferred embodiment, the present invention provides isolated or recombinant human antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof capable of specifically binding Staphylococcus species. Human antibodies and functional parts according to the invention are capable of binding Staphylococcus species in its natural context, so that various Staphylococcus species are counteracted upon administration of said antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof. Said human antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof are therefore particularly suitable for treatment or prevention of infection by such Staphylococcus species. Said human antibodies, functional parts thereof or immunoglobulin chains or functional equivalents thereof according to the invention are more suitable for therapeutic and/or prophylactic use for human individuals, as compared to chimeric antibodies, because of the absence of non-human sequences. This significantly reduces the risk of adverse side effects.
One particularly preferred antibody according to the present invention is the antibody designated "Fl", which has heavy chain and light chain variable domain sequences as depicted in Figure 1. The term "Fl" as used herein encompasses all Fl antibodies, for instance isolated or recombinantly produced Fl. Recombinantly produced Fl is herein also called "rFl". The CDR sequences of Fl, which in particular contribute to the antigen-binding properties of Fl, are also depicted in Figure 1. Antibody Fl is fully human, is capable of specifically binding Staphylococcus species such as S. aureus and S. epidermidis and is therefore preferred for therapeutic use for human individuals.
Importantly, antibody Fl is capable of binding whole bacteria in vivo as well as in vitro. Further provided is therefore an isolated or recombinant human antibody or a functional part thereof, which is capable of specifically binding S. aureus and/or S. epidermidis. Furthermore, antibody Fl is capable of binding to bacteria that have been grown in infected tissue of, for example, an animal. Provided is therefore an isolated antibody that binds to in vivo-grown S. aureus, wherein "in vivo-grown" is defined as grown in infected tissue of an animal during infection with S. aureus. Also provided is an isolated, recombinant or synthetic immunoglobulin chain or functional equivalent thereof comprising at least one CDR sequence of a human immunoglobulin variable region which is specific for S. aureus and/or S. epidermidis.
A functional part of an antibody is defined as a part which has at least one shared property as said antibody in kind, not necessarily in amount. Said functional part is capable of binding the same antigen as said antibody, albeit not necessarily to the same extent. A functional part of an antibody preferably comprises a single domain antibody, a single chain antibody, a nanobody, an unibody, a single chain variable fragment (scFv), a Fab fragment or a F(ab')2 fragment.
A functional part of an antibody is also produced by altering an antibody such that at least one property - preferably an antigen-binding property - of the resulting compound is essentially the same in kind, not necessarily in amount. This is done in many ways, for instance through conservative amino acid substitution, whereby an amino acid residue is substituted by another residue with generally similar properties (size, hydrophobicity, etc), such that the overall functioning is likely not to be seriously affected.
As is well known by the skilled person, a heavy chain of an antibody is the larger of the two types of chains making up an immunoglobulin molecule. A heavy chain comprises constant domains and a variable domain, which variable domain is involved in antigen binding. A light chain of an antibody is the smaller of the two types of chains making up an immunoglobulin molecule. A light chain comprises a constant domain and a variable domain. The variable domain is, together with the variable domain of the heavy chain, involved in antigen binding.
Complementary- determining regions (CDRs) are the hypervariable regions present in heavy chain variable domains and light chain variable domains. The CDRs of a heavy chain and the connected light chain of an antibody together form the antigen-binding site.
A functional equivalent of an immunoglobulin chain is defined herein as an artificial binding compound, comprising at least one CDR sequence of an
immunoglobulin chain.
Now that the present invention provides the insight that the CDR sequences depicted in Figure 1 provide desired binding characteristics, a skilled person is well capable of generating variants comprising at least one altered CDR sequence. For instance, conservative amino acid substitution is applied. It is also possible to alter at least one CDR sequence depicted in Figure 1 in order to generate a variant antibody, or a functional part thereof, with at least one altered property as compared to Fl. Preferably, an antibody or functional part is provided comprising a CDR sequence which is at least 70% identical to a CDR sequence as depicted in Figure 1, so that the favorable binding characteristics of Fl are at least in part maintained or even improved. A CDR sequence as depicted in Figure 1 is preferably altered such that the resulting antibody or functional part comprises at least one improved property, such as for instance an improved binding affinity, selectivity and/or stability, as compared to Fl. Variant antibodies or functional parts thereof comprising an amino acid sequence which is at least 70% identical to a CDR sequence as depicted in Figure 1 are therefore also within the scope of the present invention. Various methods are available in the art for altering an amino acid sequence. For instance, a heavy chain or light chain sequence with a desired CDR sequence is artificially synthesized.
Preferably, a nucleic acid sequence encoding a CDR sequence is mutated, for instance using random - or site-directed - mutagenesis.
In one embodiment the invention therefore provides an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof, which comprises:
- a heavy chain CDRl sequence comprising a sequence which has at least 70% sequence identity to the sequence RFAMS (SEQ ID NO:1), and/or
- a heavy chain CDR2 sequence comprising a sequence which has at least 70% sequence identity to the sequence SINNGNNPYYARSVQY (SEQ ID NO:2), and/or - a heavy chain CDR3 sequence comprising a sequence which has at least 70% sequence identity to the sequence DHPSSGWPTFDS (SEQ ID NO:3).
Further provided is an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof, which comprises:
- a light chain CDRl sequence comprising a sequence which has at least 70% sequence identity to the sequence RASENVGD WLA (SEQ ID NO:4), and/or
- a light chain CDR2 sequence comprising a sequence which has at least 70% sequence identity to the sequence KTSILES (SEQ ID NO:5), and/or
- a light chain CDR3 sequence comprising a sequence which has at least 70% sequence identity to the sequence QHYXRFPYT, wherein X is I or M (SEQ ID NO:6).
The above mentioned CDR sequences are the CDR sequences of antibody Fl; VH IgHV3-23 and VL IgKVl-5, and variants thereof. Binding compounds comprising CDR sequences with at least 70% sequence identity to Fl CDRs are particularly suitable for counteracting and/or preventing (the effects of) infections by S. aureus and/or S. epidermidis. It was found that a variant of Fl, comprising VH IgHV3-23 and VL IgKVl-5, in which the isoleucine in light chain CDR3 of the light chain was altered to a methionine, was still capable of specifically binding Staphylococcus species such as S. aureus and S. epidermidis.
Preferably, a binding compound according to the invention comprises a CDR sequence which is at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 86%, more preferably at least 87%, more preferably at least 88%, more preferably at least 89%, more preferably at least 90% identical to at least one of the CDR sequences depicted in Figure 1. Most preferably, a binding compound according to the invention comprises a CDR sequence which is at least 91%, more preferably at least 92%, more preferably at least 93%, more preferably at least 94%, more preferably at least 95% identical to at least one of the CDR sequences depicted in Figure 1. The particularly preferred antibody Fl, described above, comprises CDR sequences which consist of the CDR sequences depicted in Figure 1. A particularly preferred embodiment according to the invention thus provides an isolated, synthetic or recombinant antibody or a functional equivalent thereof which is capable of specifically binding S.aureus and/or S. epidermidis and which comprises:
- a heavy chain CDRl sequence comprising the sequence RFAMS (SEQ ID NO:1), and/or
- a heavy chain CDR2 sequence comprising the sequence SINNGNNPYYARSVQY (SEQ ID NO:2), and/or
- a heavy chain CDR3 sequence comprising the sequence DHPSSGWPTFDS (SEQ ID NO: 3), and/or
- a light chain CDRl sequence comprising the sequence RASENVGDWLA (SEQ ID NO:4), and/or
- a light chain CDR2 sequence comprising the sequence KTSILES (SEQ ID NO:5), and/or
- a light chain CDR3 sequence comprising the sequence QHYXRFPYT, wherein X is I or M (SEQ ID NO:6).
In one embodiment a binding compound is provided which comprises the heavy chain CDRl and CDR2 sequences and the light chain CDRl and CDR2 sequences as depicted in Figure 1, or sequences that are at least 70%, preferably at least 75%, more preferably at least 80%, more preferably at least 81%, more preferably at least 82%, more preferably at least 83%, more preferably at least 84%, more preferably at least 85% identical thereto. Further provided is therefore an isolated, synthetic or recombinant antibody or a functional part thereof or an immunoglobulin chain or a functional equivalent thereof which comprises a heavy chain CDRl sequence comprising a sequence which is at least 70% identical to the sequence RFAMS (SEQ ID NO:1) and a heavy chain CDR2 sequence comprising a sequence which is at least 70% identical to the sequence SINNGNNPYYARSVQY (SEQ ID NO:2) and a light chain CDRl sequence comprising a sequence which is at least 70% identical to the sequence RASENVGDWLA (SEQ ID NO:4) and a light chain CDR2 sequence comprising a sequence which is at least 70% identical to the sequence KTSILES (SEQ ID NO:5). Said binding compound preferably comprises CDR sequences which are at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 86%, more preferably at least 87%, more preferably at least 88%, more preferably at least 89%, more preferably at least 90%, more preferably at least 91%, more preferably at least 92%, more preferably at least 93%, more preferably at least 94%, most preferably at least 95% identical to the above mentioned heavy chain CDR sequences and light chain CDR sequences. Preferably, said binding compound also comprises a heavy chain CDR3 sequence comprising a sequence which is at least 70% identical to the sequence DHPSSGWPTFDS (SEQ ID NO:3), and/or a light chain CDR3 sequence comprising a sequence which is at least 70% identical to the sequence QHYXRFPYT, wherein X is I or M (SEQ ID NO:6). A binding compound comprising the above mentioned heavy chain CDRl, CDR2 and CDR3 sequences as well as the above mentioned light chain CDRl, CDR2 and CDR3 sequences is also provided.
Now that a human antibody capable of specifically binding Staphylococcus species has been provided by the present invention, it has become possible to produce an immunoglobulin chain or functional equivalent thereof comprising at least one CDR sequence of a human immunoglobulin variable domain which is specific for Staphylococcus species. Further provided is thus an isolated, recombinant or synthetic immunoglobulin chain or functional equivalent thereof comprising at least one CDR sequence of a human immunoglobulin variable region which is specific for
Staphylococcus species. In a preferred embodiment, a human antibody is provided. Optionally, said at least one human CDR sequence or at least one sequence in at least one of the framework regions is optimized, preferably in order to improve binding efficacy or stability. This is for instance done by mutagenesis experiments where after the stability and/or binding efficacy of the resulting compounds are preferably tested and an improved binding compound is selected. Besides optimizing CDR sequences in order to improve binding efficacy or stability, it is often advantageous to optimize at least one sequence in at least one of the framework regions. This is preferably done in order to improve binding efficacy or stability. Framework sequences are for instance optimized by mutating a nucleic acid molecule encoding such framework sequence where after the characteristics of the resulting antibody— or functional part— are preferably tested. This way, it is possible to obtain improved antibodies or functional parts. In a preferred embodiment, human germline sequences are used for framework regions in antibodies or functional parts thereof or immunoglobulin chains or functional equivalents according to the invention. The use of germline sequences preferably minimizes the risk of immunogenicity of said antibodies, immunoglobulin chains or functional equivalents or parts, because these sequences are less likely to contain somatic alterations which are unique to individuals from which the framework regions are derived, and may cause an immunogenic response when applied to another human individual.
Antibodies or functional parts thereof or immunoglobulin chains or functional equivalents thereof comprising a heavy chain amino acid sequence which has at least 70% sequence identity to the heavy chain sequence as depicted in Figure 1 are also provided. Such heavy chain sequence provides desired binding properties, as evidenced by antibody Fl. Moreover, light chain amino acid sequences which have at least 70% sequence identity to the light chain sequence as depicted in Figure 1, and a light chain sequence in which an isoleucine in CDR3 is altered to methionine, also provide desired binding properties, as evidenced by antibody Fl, and a variant of antibody Fl comprising said alteration. Further provided is therefore an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention, having a heavy chain sequence comprising a sequence which has at least 70% sequence identity to the sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINNGN NPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWPTFDS WGPGTLVTVSS (SEQ ID NO:7) and/or having a light chain sequence which has at least 70% sequence identity to the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSILESG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRTV, wherein in X is I or M (SEQ ID NO:8).
Several variants of the Fl antibody have been developed, besides the variant indicated herein above in which an isoleucine in light chain CDR3 is altered to methionine. These variants are capable of binding to Staphylococcus species.
Examples of such antibody variants include antibodies or functional parts or immunoglobulin chains or functional equivalents according to the invention, having a heavy chain sequence comprising the sequence
EVQLVESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINNGN NPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWPTFDS WGPGTLVTVSS (SEQ ID NO:9), and/or the sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINNGN NPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWPTFDS WGPGTLVTVSS (SEQ ID NO:7), and a light chain sequence comprising the sequence DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSILESG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRA, wherein X is I of M (SEQ ID NO:10), and/or the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSILESG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKVEIKRTV, wherein X is I of M (SEQ ID NO:11), and/or the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSILESG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRTV, wherein X is I of M (SEQ ID NO:8).
An antibody or functional part or immunoglobulin chain or functional equivalent thereof according to the invention specifically binds to proteins comprising a serine- aspartate (SD) repeat. SD repeat (Sdr) proteins are cell-surface-associated proteins that are present in several bacteria such as Staphylococcus species. Sdr proteins in general comprise an amino-rerroinal signal sequence, a functional domain caiied Hio A region, an Sl) rops-ar region, a cell wall- spanning region, a LPXTG morif, a hydrophobic meinbrane-spjnnmg domain, and a series of positively charged residues. The LFXTG mυtif is the target of a transpeptidase that cleaves the mυtif between threonine and glycine residues and anchors the protein Lo the peptidoglycan of the ceil wail of gram- posi rive bacteria. Sdr proteins are thought to interact with host molecules. Known Sdr proteins include CIfA (SdrA), CIfB (SdrB), SdrC, SdrD and SdrE of S. aureus, SdrF, SdrG and SdrH of S. epidermidis, Sdrl of S. saprophytics, SdrX of S. capitis, and SdrY and SdrZ of S. caprae.
Therefore, a preferred antibody or functional part thereof or immunoglobulin chain or functional equivalent according to the invention specifically binds S. aureus, S. epidermidis, S. sapropkyiicus, S. capitis, and S. caprae. It is preferred that said antibody, immunoglobulin chain or functional equivalent or part thereof binds to CIfA (SdrA), CIfB (SdrB), SdrC, SdrD and SdrE of S. aureus, SdrF, SdrG and SdrH of S. epidermidis, Sdrl of S. βaprophyiicus, SdrX of <S, capitis, and SdrY and SdrZ of S. caprae. The epitope of the antibody, immunoglobulin chain or functional equivalent or part thereof according to the invention comprises an SD repeat- dependent epitope in Sdr proteins, for instance SD repeat-dependent epitopes as present in S. aureus CIfA, CIfB, SdrC, SdrD and SdrE. An SD repeat- dependent epitope is herein defined as an epitope recognized by antibody Fl, which epitope require the presence of at least part of an SD repeat region as present in, but not limited to, S. aureus CIfA, CIfB, SdrC, SdrD and SdrE and S. epidermidis SdrF, SdrG and SdrH. In one embodiment said epitope may comprise at least part of a molecule that binds to, or is associated with an Sdr protein. Examples of such molecules include, but are not limited to, amino acids, peptides, proteins, sugars and sugar residues. In another embodiment, said epitope comprises modifications of the SD repeat region. Said modifications comprise, for example, but are not limited to, glycosylation, amidation and/or phosphorylation. It will be clear to a skilled person that combination of these two embodiments is also possible.
Therefore, the invention provides an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention capable of binding an SD repeat- dependent epitope. Also provided is an antibody or functional part or immunoglobulin chain or functional equivalent capable of binding to S. aureus CIfA, CIfB, SdrC, SdrD and SdrE. Further provided is an antibody or functional part or immunoglobulin chain or functional equivalent which is capable of competing with an antibody or functional part or immunoglobulin chain or functional equivalent according to the present invention for binding to a Staphylococcus species, preferably S. aureus and/or S. epidermidis and/or >S. saprcφhyiicus and/or <S. capitis and/or S. caprae, more preferably MRSA. A disadvantage of antibodies is that their stability may be reduced, for example under harsh conditions. For instance deamidation, the removal of a functional amide group, may occur. Deamidation is a protein degradation pathway that may affect the biological functions of proteins, and which occurs mainly at asparagine residues, and to a lower extent at glutamine residues. In one embodiment, therefore, deamidation of an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is prevented by replacing an asparagine or glutamine by another amino acid. An asparagine is preferably replaced by an amino acid other than glutamine, because deamidation may also occur at a glutamine residue. Replacement of an asparagine preferably does not substantially affect binding affinity of an antibody according to the invention to an antigen. In one embodiment deamidation of an asparagine at position 53 of the heavy chain (numbering according to Kabat, 1991) is prevented by replacing said asparagine by another amino acid. By preventing deamidation of an asparagine at position 53 the stability of an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is preferably increased. As is shown in the examples, despite the fact that said asparagine is located in a CDR, replacing an asparagine at said position does not substantially affect the binding affinity for an antigen of an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention. An asparagine at position 53 of the heavy chain is preferably replaced by an amino acid other than glutamine, more preferably an asparagine at said position is replaced by serine.
Therefore, also provided by the invention is therefore an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention, wherein an asparagine, preferably an asparagine at position 53 of the heavy chain, is replaced by another amino acid, preferably serine.
In one embodiment, an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is coupled to another moiety to form antibody-drug conjugates. An antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is for instance coupled to a cytotoxic agent, such as an antibiotic. The term "cytotoxic agent" as used herein refers to a substance that reduces or blocks the function, or growth, of bacteria and/or causes destruction of bacteria. Said other moiety, for example a cytotoxic agent, is preferably coupled to said antibody or functional part thereof through a thiol group. Therefore, preferably one or more cysteines are incorporated into said antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof. Cysteines contain a thiol group and therefore, incorporation of one or more cysteines into, or replacement of one or more amino acids by one or more cysteines of an antibody or functional part thereof according to the invention enable coupling thereof to another moiety. Said one or more cysteines are preferably introduced into an antibody of functional equivalent thereof according to the invention at a position where it does not influence folding of said antibody or functional equivalent, and does not alter antigen binding or effector function. The invention therefore provides an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention wherein at least one amino acid other than cysteine has been replaced by a cysteine. Preferably at least two amino acids other than cysteine have been replaced by cysteine. In a preferred embodiment, said at least one amino acid other than cysteine is valine at light chain position 15, and/or alanine at light chain position 144, and/or serine at light chain position 168, and/or valine at light chain position 205 and/or valine at light chain position 110, and/or alanine at heavy chain position 84, and/or alanine at heavy chain position 114, and/or alanine at heavy chain position 168, and/or serine at heavy chain position 172, more preferably valine at light chain position 205 and/or valine at light chain position 110, and/or alanine at heavy chain position 114 (numbering according to Kabat, 1991). A skilled person will understand that, as an alternative or in addition, one or more other amino acids of the heavy and/or light chain can be replaced by cysteine if the replacement does not influence folding of said antibody or functional equivalent, and does not alter antigen binding or effector function.
In international patent applications WO2006/034488, WO2008/141044, WO2009/052249, WO2009/012256, WO2009/012268 and WO2009/099728 methods for engineering antibodies with reactive cysteine residues are described as well as amino acid positions suitable for cysteine engineering.
An antibody or functional part or immunoglobulin chain or functional equivalent according to the invention preferably comprises a variable heavy chain sequence and/or a variable light chain sequence which is at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, most preferably at least 95% identical to a heavy chain sequence and/or the light chain sequence as depicted in Figure 1, or a light chain sequence as depicted in Figure 1 in which the isoleucine in CDR3 is altered to a methionine. The higher the identity, the more closely said binding compound resembles antibody Fl. An antibody or functional part or immunoglobulin chain or functional equivalent according to the invention preferably comprises a heavy chain as well as a light chain which resemble the heavy and light chain of Fl. Further provided is therefore an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof comprising a heavy chain sequence and a light chain sequence which are at least 70%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, most preferably at least 95% identical to the heavy chain sequence and the light chain sequence as depicted in Figure 1, or a light chain sequence as depicted in Figure 1 in which the isoleucine in CDR3 is altered to a methionine. In one embodiment an antibody or functional part is provided which has a heavy chain sequence as depicted in Figure 1 and a light chain sequence as depicted in Figure 1 or a light chain sequence as depicted in Figure 1 in which the isoleucine in CDR3 is altered to a methionine.
One embodiment provides an antibody or functional part thereof or
immunoglobulin chain or functional equivalent thereof comprising a heavy chain sequence consisting of the heavy chain sequence as depicted in Figure 1, and/or comprising a light chain sequence consisting of the light chain sequence as depicted in Figure 1 or a light chain sequence as depicted in Figure 1 in which the isoleucine in
CDR3 is altered to a methionine. Alternatively, as is well known by the skilled person, it is possible to generate a shortened heavy chain or light chain sequence while maintaining a binding property of interest. Preferably, such a shortened heavy chain or light chain is generated which has a shorter constant region, as compared to the original heavy or light chain. The variable domain is preferably maintained. For instance, a Fab fragment or F(ab')2 fragment or a single domain antibody or a single chain antibody or a nanobody or an unibody or a scFv fragment based on a heavy chain sequence or light chain sequence depicted in Figure 1 is produced. A functional part of an antibody comprising at least a functional part of a sequence as depicted in Figure 1, or a light chain sequence as depicted in Figure 1 in which the isoleucine in CDR3 is altered to a methionine, is therefore also provided. Said functional part has a length of at least 20 amino acids and comprises at least one sequence selected from the group consisting of a sequence which is at least 70% identical to the heavy chain CDRl sequence depicted in Figure 1 and a sequence which is at least 70% identical to the heavy chain CDR2 sequence depicted in Figure 1 and a sequence which is at least 70% identical to the heavy chain CDR3 sequence depicted in Figure 1 and a sequence which is at least 70% identical to the light chain CDRl sequence depicted in Figure 1 and a sequence which is at least 70% identical to the light chain CDR2 sequence depicted in Figure 1 and a sequence which is at least 70% identical to the light chain CDR3 sequence depicted in Figure 1, or a light chain CDR3 sequence as depicted in Figure 1 in which the isoleucine is altered to a methionine. The invention further provides an isolated, synthetic or recombinant nucleic acid sequence or a functional equivalent thereof with a length of at least 15 nucleotides, preferably at least 30 nucleotides, more preferably at least 50
nucleotides, more preferably at least 75 nucleotides, encoding a binding compound according to the invention. Such nucleic acid is for instance isolated from a B-cell which is capable of producing an antibody according to the invention. A preferred embodiment provides a nucleic acid sequence comprising a sequence which has at least 70% sequence identity to at least 15 nucleotides of a nucleic acid sequence as depicted in Figure 1. A nucleic acid sequence according to the invention preferably comprises a sequence which has at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, most preferably at least 95% sequence identity to at least 15 nucleotides of a nucleic acid sequence as depicted in Figure 1. Preferably, said nucleic acid sequence as depicted in Figure 1 comprises at least one CDR encoding sequence.
One preferred embodiment provides an isolated, synthetic or recombinant nucleic acid sequence with a length of at least 15 nucleotides, or a functional equivalent thereof, encoding at least one CDR sequence of an antibody or
immunoglobulin chain according to the invention. Said nucleic acid sequence preferably encodes at least one CDR sequence which has at least 70% sequence identity to a CDR region of antibody Fl. Nucleic acid sequences encoding Fl CDR regions are depicted in Figure 1. Further provided is therefore an isolated, synthetic or recombinant nucleic acid sequence, or a functional equivalent thereof, comprising a sequence which has at least 70% sequence identity to a sequence selected from the group consisting of cgctttgccatgagc (SEQ ID NO:12),
tcgatcaataatgggaataacccatactacgcacggtcggtacaatac (SEQ ID NO:13),
gatcaccctagtagtggctggcccacctttgactcc (SEQ ID NO: 14),
cgggccagtgaaaacgttggtgactggttggcc (SEQ ID NO: 15), aagacatctattctagaaagt (SEQ ID NO: 16) and caacactatatacgtttcccgtacact (SEQ ID NO: 17).
Said nucleic acid sequence or functional equivalent preferably comprises a sequence which has at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90% sequence identity to any of the above mentioned sequences. Further provided is a nucleic acid sequence or functional equivalent thereof comprising a sequence which has at least 70% sequence identity to at least part of a nucleotide sequence as depicted in Figure 1, said part having at least 15 nucleotides and encoding at least one CDR region.
A nucleic acid sequence or functional equivalent thereof according to the present invention preferably encodes a region which has at least 70% sequence identity to an Fl CDR region, an Fl heavy chain and/or an Fl light chain. One embodiment thus provides an isolated, synthetic or recombinant nucleic acid sequence, or a functional equivalent thereof, comprising a sequence encoding an amino acid sequence which has at least 70% sequence identity to the sequence RFAMS (SEQ ID NO:1), and/or at least 70% sequence identity to the sequence SINNGNNPYYARSVQY (SEQ ID NO:2), and/or at least 70% sequence identity to the sequence DHPSSGWPTFDS (SEQ ID NO:3), and/or at least 70% sequence identity to the sequence RASENVGD WLA (SEQ ID NO:4), and/or at least 70% sequence identity to the sequence KTSILES (SEQ ID NO:5), and/or at least 70% sequence identity to the sequence QHYXRFPYT, wherein X is I or M (SEQ ID NO:6), and/or at least 70% sequence identity to the sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINNGN NPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWPTFDS WGPGTLVTVSS (SEQ ID NO:7), and/or at least 70% sequence identity to the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSILESG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRTV, wherein X is I or M (SEQ ID NO:8). Also provided are nucleic acid sequences or functional equivalents thereof encoding variants of the Fl antibody according to the invention. Provided by the invention are, for example, nucleic acid sequences encoding a heavy chain sequence comprising the sequence
EVQLVESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINNGN NPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWPTFDS WGPGTLVTVSS (SEQ ID NO:9), and/or the sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINNGN NPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWPTFDS WGPGTLVTVSS (SEQ ID NO:7), and encoding a light chain sequence comprising the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSILESG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRA, wherein X is I of M (SEQ ID NO: 10), and/or the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSILESG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKVEIKRTV, wherein X is I of M (SEQ ID NO:11), and/or the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSILESG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRTV, wherein X is I of M (SEQ ID NO:8).
In one embodiment an asparagine at position 53 of the heavy chain
(numbering according to Kabat, 1991) is replaced by another amino acid other than glutamine, in order to prevent deamidation of the asparagine at said position.
Preferably said asparagine is replaced by a serine.
The term "% sequence identity" is defined herein as the percentage of residues in a candidate amino acid of nucleic acid sequence that is identical with the residues in a reference sequence after aligning the two sequences and introducing gaps, if necessary, to achieve the maximum percent identity. Methods and computer programs for the alignment are well known in the art.
As used herein, a nucleic acid molecule or nucleic acid sequence of the invention preferably comprises a chain of nucleotides, more preferably DNA and/or RNA. In other embodiments a nucleic acid molecule or nucleic acid sequence of the invention comprises other kinds of nucleic acid structures such as for instance a DNA/RNA helix, peptide nucleic acid (PNA), locked nucleic acid (LNA) and/or a ribozyme. Such other nucleic acid structures are referred to as functional equivalents of a nucleic acid sequence. The term "functional equivalent of a nucleic acid sequence" also encompasses a chain comprising non-natural nucleotides, modified nucleotides and/or non-nucleotide building blocks which exhibit the same function as natural nucleotides. A nucleic acid sequence according to the present invention is particularly useful for generating binding compounds which are specific for S. aureus and/or S. epidermidis. This is for instance done by introducing such nucleic acid sequence into a cell so that the cell's nucleic acid translation machinery will produce the encoded binding compound. In one embodiment, genes encoding a heavy and/or light chain according to the invention are expressed in so called producer cells, such as for instance cells of a Chinese hamster ovary (CHO), NSO (a mouse myeloma) or 293(T) cell line, some of which are adapted to commercial antibody production. Proliferation of said producer cells results in a producer cell line capable of producing antibodies or functional parts thereof according to the present invention. Preferably, said producer cell line is suitable for producing compounds for use in humans. Hence, said producer cell line is preferably free of pathogenic agents such as pathogenic micro-organisms. Most preferably, binding compounds consisting of human sequences are generated using a nucleic acid sequence according to the invention. An isolated or recombinant antibody producing cell capable of producing an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention is therefore also provided, as well as a method for producing an antibody or functional part or immunoglobulin chain or functional equivalent according to the invention, comprising providing a cell with a nucleic acid sequence or functional equivalent according to the invention and allowing said cell to translate said nucleic acid sequence or functional equivalent according to the invention, thereby producing said antibody or functional part or immunoglobulin chain or functional equivalent according to the invention.
An antibody producing cell is defined herein as a cell which is capable of producing and/or secreting an antibody or a functional part thereof, and/or which is capable of developing into a cell which is capable of producing and/or secreting antibody or a functional part thereof. An antibody producing cell according to the invention is preferably a producer cell which is adapted to commercial antibody production. Preferably, said producer cell is suitable for producing compounds for use in humans.
A method according to the invention preferably further comprises a step of harvesting, purifying and/or isolating said antibody or functional part or
immunoglobulin chain or functional equivalent according to the invention. The thus obtained binding compounds according to the invention are preferably used in diagnosis of Staphylococcus infection, isolation or detection of Staphylococcus bacteria, distinguishing between Staphylococcus species and other gram-positive bacteria and human therapy, optionally after additional purification, isolation and/or other processing steps.
An antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the present invention is particularly suitable for diagnostic uses. For instance, a sample, such as a tissue or blood sample, can be obtained from an individual or from any other source suspected to be infected with a Staphylococcus bacteria, preferably S. aureus and/or S. epidermidis, more preferably MRSA. Subsequently, said sample can be mixed with an antibody or immunoglobulin chain or functional equivalent or part thereof according to the invention. Said antibody, immunoglobulin chain or functional equivalent or part will specifically bind to Staphylococcus bacteria, preferably S. aureus and/or S. epidermidis. Bacteria bound to an antibody, immunoglobulin chain or functional equivalent or part can be isolated from the sample using any method known in the art, for example, but not limited to, isolation using magnetic beads, streptavidin-coated beads, or isolation through the use of secondary antibodies immobilized on a column. After washing of the bound bacteria and antibody, immunoglobulin chain or functional equivalent or part thereof, bacteria can be eluted from said antibody, immunoglobulin chain or functional equivalent or part by any method known in the art. For instance, binding between bacteria and antibody, immunoglobulin chain or functional equivalent or part can be disrupted by increasing the concentration of salts and/or reducing or increasing pH, and/or by addition of excess epitope.
Isolation of Staphylococcus bacteria, preferably S. aureus and/or S.
epidermidis, may be used for various applications. For instance, infection with several different gram-positive bacteria may result in overlapping symptoms in an individual. In such cases, it can be difficult to discriminate between S. aureus and/or S.
epidermidis and other gram-positive bacteria. An antibody, immunoglobulin chain or functional equivalent or part thereof according to the present invention can then be used to detect the presence of S. aureus and/or S. epidermidis, or for distinguishing between S. aureus and/or S. epidermidis and other bacteria. Isolation of bacteria from a sample of an individual suspected of suffering from an infection with S. aureus and/or S. epidermidis or from any other source, such as a bacterial culture, can facilitate detection of said Staphylococcus bacteria, because isolation results in an increased concentration and/or a higher purity of said Staphylococcus bacteria.
Isolation of Staphylococcus species, preferably S. aureus and/or S. epidermidis, more preferably MRSA, can for instance further be used to identify the specific S. aureus and/or S. epidermidis strain, preferably the MRSA strain in a sample.
Identification of said strain can for instance be performed by determining the sequence of the bacterial DNA. In such case it is preferred to first obtain an isolated S. aureus and/or S. epidermidis.
In one embodiment of the invention, an antibody, immunoglobulin chain or functional equivalent or part thereof according to the present invention is labeled in order to be able to detect said antibody, immunoglobulin chain, or functional equivalent or part, for instance, but not limited to, fluorescently labeled, or radioactively labeled. Alternatively, an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention is detected using a labeled secondary antibody which is directed against said antibody, immunoglobulin chain or functional equivalent or part thereof according to the invention. If binding of said antibody, immunoglobulin chain or functional equivalent or part thereof is detected, S. aureus and/or S. epidermidis is present.
Provided by the invention is therefore a use of an antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof according to the invention for diagnosis of a Staphylococcus infection, preferably S. aureus infection, more preferably MRSA infection, for detecting S. aureus and/or S. epidermidis, preferably MRSA, and for distinguishing between S. aureus and/or S. epidermidis, preferably MRSA and other gram-positive bacteria. Also provided is an antibody or functional part thereof or an immunoglobulin chain or functional equivalent thereof according to the invention for use in the diagnosis of a Staphylococcus infection, preferably S. aureus infection, more preferably MRSA infection.
Further provided is a method for isolating S. aureus and/or S. epidermidis bacteria from a solution using an antibody or functional part or an immunoglobulin chain or functional equivalent thereof according to the invention. Said method preferably comprises providing a sample of an individual suspected of suffering from an infection with S. aureus and/or S. epidermidis, preferably MRSA, or from any other source, such as a bacterial culture, adding an antibody or functional part or an immunoglobulin chain or functional equivalent thereof according to the invention to said sample, allowing binding of said antibody or functional part or an
immunoglobulin chain or functional equivalent thereof according to the invention to S. aureus and/or S. epidermidis bacteria, when present, and isolating S. aureus and/or S. epidermidis bacteria bound to an antibody or functional part or an immunoglobulin chain or functional equivalent thereof according to the invention from said sample.
Now that Gram-positive bacteria- specific binding compounds according to the invention and nucleic acid sequences coding therefore have been provided, including human binding compounds, improved therapeutic applications have become available. Gram-positive bacteria such as S. aureus and/or S. epidermidis are counteracted by binding compounds according to the invention. A binding compound according to the invention is therefore particularly suitable for use as a medicine or prophylactic agent. Preferably, binding compounds are used which consist of human sequences, or which have at most 5% of non-human sequences, in order to reduce the chance of adverse side effects when human individuals are treated. An antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to the invention for use as a medicament and/or prophylactic agent is therefore also herewith provided. When a nucleic acid or functional equivalent according to the invention is administered, it will be translated in situ into a binding compound according to the invention. In a particularly preferred embodiment said antibody comprises antibody Fl, or a functional part thereof. Said medicament or prophylactic agent is preferably used for counteracting or at least in part preventing an infection by S. aureus and/or S.
epidermidis or for counteracting or at least in part preventing adverse effects of an infection by S. aureus and/or S. epidermidis. Further provided is therefore an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to the invention for use as a medicament and/or prophylactic agent for at least in part treating and/or preventing a condition related to S. aureus and/or S. epidermidis.
Non-limiting examples of such conditions are skin infections, pimples, impetigo, boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome, abscesses, pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome and septicemia. Preferably, S. aureus infection is counteracted or at least in part prevented. Most preferably, an MRSA-related condition is counteracted, diminished and/or at least in part prevented. A use of an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to the invention for the preparation of a medicament and/or prophylactic agent for at least in part treating and/or preventing S. aureus and/or S. epidermidis is therefore also provided, as well as a method for at least in part treating or preventing a condition related to S. aureus and/or S.
epidermidis, the method comprising administering to an individual in need thereof a therapeutically effective amount of an antibody or functional part or an immunoglobulin chain or functional equivalent according to the invention, preferably after said individual has been diagnosed to be infected by S. aureus and/or S.
epidermidis. Said condition preferably comprises at least one of the S. aureus-related conditions listed above, most preferably an MRSA-related condition.
Said antibody preferably comprises antibody Fl, or a functional part thereof.
In order to counteract Gram-positive bacteria, a binding compound according to the invention is preferably administered to an individual before an infection has taken place. Alternatively, a binding compound according to the invention is administered when an individual is already infected. Said binding compound is preferably administered to individuals with an increased risk of complications, such as for instance hospitalized individuals and/or individuals with compromised immunity. Also elderly people have an increased risk of bacterial conditions. Binding compounds according to the invention are preferably administered via one or more injections. Dose ranges of binding compounds according to the invention to be used in the therapeutic applications as described herein before are designed on the basis of rising dose studies in the clinic in clinical trials for which rigorous protocol requirements exist. Typical doses are between 0.1 and 10 mg per kg body weight. For therapeutic application binding compounds according to the invention are typically combined with a pharmaceutically acceptable carrier, diluent and/or excipient.
Examples of suitable carriers for instance comprise keyhole limpet haemocyanin (KLH), serum albumin (e.g. BSA or RSA) and ovalbumin. In one preferred embodiment said suitable carrier comprises a solution like for example saline. In yet another embodiment a nucleic acid encoding a binding compound according to the invention is used. As already described, upon administration of such nucleic acid, binding compounds are produced by the host's machinery. Produced binding compounds are capable of preventing and/or counteracting Gram-positive bacterial infection and/or the adverse effects of such infection. A nucleic acid sequence or functional equivalent according to the invention for use as a medicament and/or prophylactic agent is therefore also herewith provided. Said nucleic acid is preferably used for counteracting S. aureus and/or S. epidermidis, more preferably S. aureus, most preferably MRSA. Further provided is therefore a use of a nucleic acid sequence or functional equivalent according to the invention for the preparation of a medicament and/or prophylactic agent for at least in part treating and/or preventing a Gram-positive bacterium-related condition. Said Gram-positive bacterium-related condition preferably comprises an infection by S. aureus or S. epidermidis, more preferably an S. aureus infection, most preferably an MRSA infection.
Further provided is a pharmaceutical composition comprising an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to the invention and a pharmaceutical acceptable carrier, diluent or excipient. Said pharmaceutical composition is preferably suitable for human use.
The invention is further explained in the following examples. These examples do not limit the scope of the invention, but merely serve to clarify the invention.
All patent documents and other publications that are referred to in the detailed description are incorporated herein by reference for all purposes.
Examples
Example 1 METHODS
B cell isolation
B-cells were obtained from fresh blood of adults by Ficoll separation and
CD4/CD8 negative selection with MACS microbeads as described by the manufacturer (Miltenyi Biotech). To obtain memory B cells, cells were sorted for CD19+CD3
CD27+IgD IgA on a FACSaria (Becton Dickinson). The use of these tissues was approved by the medical ethical committees of the institution and was contingent on informed consent. Donors were selected based on carrying hospital acquired MRSA strains with genotype cluster 109 and 16.
Cell culture
B-cells maintained in standard culture medium containing IMDM (Gibco), 8%
FBS (HyClone) and penicillin/streptomycin (Roche) were co-cultured on γ-irradiated
(50Gy) mouse L cell fibroblasts stably expressing CD40L (CD40L-L cells, 105 cells/ml) and recombinant mouse IL-21 (25ng/ml, R&D systems). rhIL-4 (R&D) was used at
50ng/ml. Cells were routinely tested by PCR and were found negative for the presence of mycoplasma and EBV (data not shown).
Bulk transduced human memory B cells double positive for NGFR and GFP were purified by FACS cell sorting and cultured in 96 well plates at a cell density of 500 cell per well. Culture supernatants were tested in ELISAs using bacterial lysates of the Newman and SHlOOO strains. Positive cultures were subcloned at 10 cell/well cell density in 96 well plates and again tested by ELISA. Subsequently positive cultures were seeded at 1 cell per well and tested again by ELISA for reactivity against S. aureus strains Newman and SHlOOO. Retroviral transduction
The BCL6 retroviral construct has been described before (Shvarts A. et al. Genes Dev 16, 681-686 (2002)). cDNA encoding human Bcl-xL was kindly provided by Dr. Stanley Korsmeyer. BCL6 and Bcl-xL were separately cloned into a BCL6-NGFR and a BcIxL- GFP construct. These constructs were transfected into the LZRS retroviral packaging cells, phoenix as described before (Jaleco A. C. et al. Blood 94, 2637-2646 (1999);
Scheeren F.A. et al. Nat Immunol 6, 303-313 (2005)). Memory B-cells were double transduced by the BCL6 and Bcl-xL containing retroviruses after activation on CD40L-L cells in the presence of rmIL-21 for 36 hrs as described before (Diehl S. A. et al. J Immunol 180, 4805-4815 (2008); Kwakkenbos M. et al. Nat Med in press (2009)). Transduced cells were maintained on CD40L-L cells with rmIL-21.
ELISA
To determine antibody content ELISA plates were coated with anti-human IgG (Jackson ImmunoResearch Laboratories) at 5 μg/ml in PBS for lhr at 37°C or o/n at 4°C and washed in ELISA wash buffer (PBS, 0.5% Tween-20). 4% milk in PBS was used as blocking agent, before serial dilution of cell culture supernatants and an enzyme-conjugated detection antibody was added (dilution 1:2500 for HRP-conjugated anti-IgG (Jackson)). TMB substrate/stop solution (Biosource) was used for
development of the ELISAs.
For screening purposes we used lysates from the Newman and SHlOOO strains. Both were made in PBS and directly coated at 5 to 10 μg ml λ before B cell culture supernatants were tested un- or 1:2 diluted.
To explore the antigen specificity of the human IgGl clone Fl, an LTA detection ELISA was developed. Purified LTA preparations from S. aureus, B.
subtilis, S. faecalis and S. pyogenes (Sigma) was added to ELISA plates coated with polyclonal IgG purified mouse anti-LTA (1/200 stock 1 mg ml \ QED Bioscience), before secondary antibodies were added.
In addition, we tested several LTA preparations derived from a library developed by W. Fischer (Institut fur Biochemie, Univ of Erlangen, Germany) and kindly provided by B. Appelmelk (VU, Amsterdam, Netherlands) (see for more details (Keller R. et al. Infect Immun 60, 3664-3672 (1992), Polotsky V. Y. et al. Infection and Immunity 64, 380-383 (1996) and Greenberg J. W. et al. Infection and Immunity 64, 3318-3325 (1996)) and reviewed in (Weidenmaier C. et al. Nat Rev Microbiol 6, 276- 287 (2008)) in direct ELISA's. LTA preparations were coated at 1 μg ml x before rFl (10 μg ml x) or control antibodies (1:5 dilution of hybridoma supernatant) were added and further detected with conjugated anti-human or mouse antibodies. The panel of purified LTA preparations included: B. subtilis, S. aureus, L. lactis, L. garυieae, B. bifidum, M. luteus, L. casei, L. mesenteroides, B. licheniformis, L. welshimeri, E. hirae, L. raffinolactis, S. mutans, S. pneumoniae. Several variants contain or lack alanine residues and/or lipid anchors (not depicted here). Binding of the Fl antibody to bacterial cultures
The Newman S. aureus and the S. pneumoniae strain (serotype 3) were used. Newman was cultured in TSH 50 ml O/N, then 1 ml was resuspendend in 100 ml for 2 to 2.5 hrs till OD:1 and bacteria were collected. S. pneumoniae was cultured in Todd Hewitt medium mixed with yeast medium. Before, bacteria were incubated with Fl antibody, a control IgG (D25, a human anti-RSV antibody) or only with the secondary antibody (IgG-PE only), cells were pretreated with 100% total mouse serum to prevent background staining. After washing the secondary antibody was added (IgG-PE). Antibody incubations were performed for 20 min on ice. Fl sequence determination and expression cloning
We isolated total RNA using Trizol (Invitrogen), generated cDNA by using superscript RT, performed PCR and cloned the heavy and light chain variable regions into the pCR2.1 TA cloning vector (Invitrogen). To rule out reverse transcriptase or DNA polymerase induced mutations, we performed several independent cloning experiments. To produce recombinant Fl mAb we cloned Fl heavy and light variable regions in frame with human IgGl and Kappa constant regions into a pcDNA3.1 (Invitrogen) based vector and transiently transfected 293T cells. We purified recombinant Fl from the culture supernatant with Protein A.
RESULTS
Generation of the Fl clone From three subjects who were tested positive for MRSA but were not sick, 50-60ml of heparin blood was collected and peripheral B-cells were isolated after a ficoll purification step. B-cells from several B-cell populations were double transduced with retroviruses containing BCL6-NGFR and Bcl-xL-GFP (Diehl et al and Kwakkenbos et al). From the IgG, CD27 positive population, polyclonal mini-cultures B-cell cultures were started in 96 wells plate with a cell density of 500 cells/well. Supernatant of these mini-cultures was collected and used in ELISAs to screen for the presence of S. aureus-specific IgG antibodies (in these ELISAs the coating was cell lysates of two S. aureus strains, SHlOOO and Newman). Mini-cultures that were screened positive in both the SHlOOO as well as the Newman S. aureus were seeded in new mini-cultures at a density of 10 cells/well. Again, supernatant of these mini-cultures was collected and screened in the SHlOOO and Newman ELISAs. Clones that were screened positive in both ELISAs were seeded into monoclonal cultures (i.e. 1 cell/well). After testing the supernatant of these monoclonal cultures, one clone (named Fl) was found to produce S. aureus specific monoclonal IgG antibodies.
Antibodies in the supernatant of the Fl clone bind to LTA preparations from S. aureus
Generating the Fl clone, we already found that supernatant of Fl bound to the bacterial cell lysates of two S. aureus strains, SHlOOO and Newman. The major cell wall compound of Gram-positive bacteria is LTA, and therefore we decided to test binding of Fl supernatant to S. aureus LTA preparations in an ELISA. As shown in Table 1, supernatant of the Fl clone binds to bacterial cell lysates of the SHlOOO and Newman S. aureus strain but also to commercially purchased purified S. aureus LTA preparations. We noted, however, that the binding to the LTA preparations was significantly lower than that observed with whole bacteria. Table 1: Supernatant of the Fl clone binds to S. aureus LTA preparations. As a negative control an anti-mouse-HRP conjugated secondary antibody was used.
Another control was an anti-influenza virus antibody that only detected influenza H3 protein.
mouse anti-flu
F1 clone anti-LTA control
SH 1000 1 ,004 -0,01 0 -0,007
Newman 0,753 -0,007 0,007
SA LTA (siαm 0, 1 76 -0,005 -0,009
Flu H3 0,003 -0,002 1 ,523
No coat -0,013 -0,014 -0,01 5
The recombinant produced Fl antibody binds to LTA preparations from multiple sources
After cloning the antibody genes into expression vectors and producing recombinant Fl (rFl) antibody in an expression system, the rFl antibody was tested on purified LTA preparations from several bacteria. As shown in Figure 2A, the rFl antibody binds well to commercial LTA samples obtained from S. aureus and B. subtilis, and a bit less profoundly to LTA samples from S. faecalis and S. pyogenes. The rFl antibody did not bind to an LTA sample from S. pneumoniae (data not shown). In addition rFl recognized highly purified LTA samples from B. subtilis, B. licheniformis and two isolates of S. aureus (Figure 2b). rFl did not bind to LTA preparations from S. mutans (Fig. 2b) or from L. lactis, L. garυieae, B. bifidum, M. luteus, L. casei,
L. mesenteroides, L. welshimeri, E. hirae, L. raffinolactis, S. mutans and
S. pneumoniae (results not shown).
Recombinant Fl antibody binds to living S. aureus bacteria
In order to study whether the rFl antibody would also recognize living Gram-positive bacteria, binding of the rFl antibody to S. aureus and S. pneumoniae was tested by using flow cytometry. As shown in figure 3A, the rFl antibody binds to living S. aureus bacteria (Newman strain), but not to S. pneumoniae. In addition we show that rFl recognized 6 clinical S. aureus isolates; one is a pathogenic strain which is PVL positive, 3 regular strains and 2 MRSA strain (Figure 3b).
Example 2 METHODS Bacterial strains and culture.
Methicillin-resistant S. aureus (MRSA) strains USA300 (1114), USA400, N315, USAlOO, USAlOOO, COL, MRSA252, as well as methicillin- sensitive S. aureus (MSSA) strains Reynolds, Becker, Smith Diffuse, MN8, and vancomycin intermediate sensitive (VISA) strain Mu50, were all obtained from the Network on Antibiotic Resistance in Staphylococcus aureus (NARSA); MSSA strains Newman and
Rosenbach were from ATCC. Staphylococcus epidermidis, Bacillus subtilis,
Enterococcus faecalis, and Streptococcus pyogenes were obtained from Ward's Natural Science; Listeria monocytogenes was from ATCC. Bacteria were grown on tryptic soy agar (TSA) plates supplemented with 5% sheep blood for 18 h at 37 0C. For liquid cultures, single colonies from TSA plates were inoculated into tryptic soy broth (TSB) and incubated at 37 0C while shaking at 200 rpm for 18 h. Fresh 100-fold dilutions of these cultures in fresh TSB were further subcultured for various times.
FACS analysis of rFl binding to whole bacteria grown in vitro.
For antibody staining of whole cells, bacteria were harvested from TSA plates or TSB cultures, and washed with Hank's Buffered Salt Solution (HBSS) without phenol red supplemented with 0.1% BSA (IgG free; Sigma) and 10 mM Hepes, pH 7.4 (HB buffer), by centrifugation at 1700 x g for 20 min. Bacterial concentrations were estimated by reading optical density at 630 nm. Bacterial suspensions of 2OxIO8 CFU/mL in HB buffer were mixed with equal volumes of 300 μg/mL of rabbit IgG (Sigma), and incubated for 1 h at room temperature (RT) to block nonspecific IgG binding. Primary antibodies, including rFl and a human IgGl isotype control, were added to a final concentration of 2 μg/mL, and these mixtures were incubated for 15 min at RT. After two washes with HB, bacterial pellets were resuspended in a solution of fluorescent anti-human IgG secondary antibodies (Jackson
Immunoresearch) and incubated for 15 min at RT. The bacteria were washed twice with PBS, resuspended in PBS with 1% paraformaldehyde, and analyzed by flow cytomery.
FACS analysis of rFl binding to whole bacteria from infected tissues.
For analysis of antibody binding to bacteria from infected tissue, 4 h subcultures of USA300 in TSB were washed with PBS. Mice were injected intravenously with a 100 μL of a suspension of USA300 in PBS with an estimated concentration of 1OxIO8 CFU/mL. Three days later, kidneys, livers, and lungs were harvested and homogenized using conical tissue grinder tubes (VWR). When indicated, organs were harvested at different time points of infection. To lyse mouse cells, the homogenates were incubated for 10 min at RT in PBS containing 0.1% Triton-XIOO (Thermo), 10 μg/mL of DNAseI (Roche) and Complete Mini protease inhibitor cocktail (Roche), and passed through a 40 μm filter (Falcon). The cell suspensions were washed twice with PBS and resuspended in HB buffer, mixed with equal volumes of 600 μg/mL of human IgG (Sigma), and incubated for 1 h at RT. Primary Abs, including rFl and a human IgGl isotype control, were added to a final concentration of 2 μg/mL. To differentiate bacteria from mouse organ debris, rabbit IgG anti-S. aureus (Abeam) was added to a concentration of 20 μg/mL. After incubation for 15 min at RT, cells were washed twice with HB buffer, and resuspended in a mixture of anti-human IgG and anti-rabbit IgG secondary antibodies, each labeled with a different fluorochrome (Jackson Immunoresearch). After two washes with PBS, cells were resuspended in PBS with 2%
paraformaldehyde and analyzed by flow cytometry. After selecting bacteria from double fluorescence plots by gating for positive staining with rabbit IgG anti-S. aureus, overlay histogram plots of fluorescence intensities of rFl and isotype control were generated.
RESULTS rFl binds strongly to 14 S. aureus strains and S. βpidβrmidis Seven Methicillin-resistant S. aureus (MRSA) strains, six methicillin- sensitive S. aureus (MSSA) strains, one vancomycin intermediate sensitive S. aureus (VISA) strain, S. epidermidis and several other gram-positive species were tested for binding to rFl antibody. As shown in figure 4, rFl strongly binds to all 14 S. aureus strains (figure 4A) and to S. epidermidis (figure 4B), but not to the other tested gram- positive species (figure 4B). rFl binds to MRSA from different growth stages and from in vivo infection
We tested the ability of mAb rFl to bind to bacteria both in different tissues and over the course of infection. We found that rFl bound to bacteria isolated from murine kidney, liver and lung tissue two days after infection and that the binding to bacteria isolated from infected kidneys was stable, binding bacteria 2, 3 and 8 days after infection.
Binding of rFl antibody to different growth stages of MRSA (strain USA300), namely early logarithmical growth (2 hours) and post exponential growth (8 hours) in TSB cultures, and growth of solid colonies on TSA plates was tested. rFl strongly binds to all growth stages tested (figure 5A).
Binding of rFl antibody to MRSA (strain USA300) to whole bacteria from infected tissue was tested in homogenized kidneys from mice three day after the mice were systemically infected with MRSA. As shown in figure 5B rFl binds to MRSA obtained from infected tissue.
Example 3
Further experiments were performed to identify the epitope bound by antibody rFl. Although binding to LTA preparations had been observed (see, e.g.,
Example 1), that binding was not as robust as binding to whole bacteria suggesting that another epitope may be involved in rFl binding. METHODS
Immunoprecipitation, Western blotting and mass spectrometry of cell wall lysates of S. aureus and S. epidermidis and commercial WTA preparation
40 micrograms of a commercial wall teichoic acid (WTA) preparation from
Wood46 S. aureus strain (Biodesign/ Meridian Life Sciences, Maine) was split into two parts and immunoprecipitated with 1 ug/ml of rFl or isotype control human antibody. Antibodies were captured with Protein A/G Ultralink Resin (Pierce). The samples were then treated with 5OmM dithiothreitol, 1OmM 2-Iodoacetamide and run on an 8% Tris-glycine gel and subsequently Western blotted with rFl.
A cell wall preparation of a 20 ml overnight culture of USA300 S. aureus strain was prepared by treatment of the culture (40 mg cell pellet/ml) with 100mg/ml of lysostaphin in 30% raffinose buffer at 37°C for 30 minutes. The entire cell wall prep was filtered, diluted up to 10 ml with NP40 Lysis buffer and incubated twice with anti-Flag M2 Agarose (Sigma) to deplete as much protein-A from the cell wall prep as possible. Final cell wall preparation was split into two parts and
immunoprecipitated with 1 ug/ml of rFl or isotype control human antibody.
Antibodies were captured with Protein A/G Ultralink Resin (Pierce). The samples were then treated with 5OmM dithiothreitol, 1OmM 2-Iodoacetamide and run on an 8% Tris-glycine gel and subsequently silver stained or Western blotted with rFl.
Lysates from a 20 ml overnight culture of Staphylococcus epidermidis was prepared by bead beating in NP40 Lysis Buffer. The resulting lysate preparation was diluted to 10 ml with NP40 Lysis Buffer, split into two parts and immunoprecipitated with 1 ug/ml of rFl or control antibody. Antibodies were captured with Protein A/G Ultralink Resin (Pierce). The samples were then treated with 5OmM dithiothreitol, 1OmM 2-Iodoacetamide and run on an 8% Tris-glycine gel and subsequently silver stained or Western blotted with rFl.
For proteomic analysis, samples were applied to a precast SDS PAGE mini gel and the resolved proteins stained with Coomassie Blue. Gel slices from the region of the gel corresponding to bands visualized by rFl western blot were excised and reduced, alkylated with iodoacetamide, and digested in situ with trypsin. Resulting tryptic peptides were analyzed by microcapillary reverse-phase liquid
chromatography- nano electrospray tandem mass spectrometry on a hybrid linear ion trap Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FT; Thermo Fisher) in a data- dependent experiment. Tandem mass spectral results were submitted for database searching using Mascot software (Matrix Science).
Expression of exogenous CIfA expressed in S. aureus and E. coli
S.aureus expression of His -tagged CIfA: The Clumping factor- A (CIfA) gene was PCR amplified from the sequence encoding the signal sequence to the sequence encoding the glycine in the LPXTG motif from USA300 genomic DNA. A c-terminal His Tag was engineered at the end of the LPXTG motif and ligated into the pTet S.aureus expression vector (pSASlO from Genentech). The resulting construct was then electroporated into S. aureus WT RN4220. A 20 ml culture of either the electroporated RN4220 or RN4220 empty (not carrying a pTet expression vector) was inoculated from an overnight culture (starting ODβoo of 0.15), grown for 1 hr in trypticase soy broth (TSB) and then induced protein expression for 2 hrs with anhydrotetracycline (200 ng/ml). At the end of the induction period, the S. aureus culture was pre-lysed with lysostaphin (50 ug/ml) and then further lysed by bead beating in lysis buffer (150 mM NaCl, 20 mM Tris pH 7.5, 1% triton-X, and Roche protease inhibitor EDTA-free tablets). Cleared lysates were then incubated with NiNta resin (Qiagen) in the presence of 10 mM Imidazole for 1 hr at 4°C to pull-down the recombinant CIfA protein. E. coli expression of His -tagged CIf a: The Clumping factor- A (CIfA) gene was
PCR amplified from the sequence encoding the N-term signal sequence (with the start methionine) to the sequence encoding the glycine in the C-term LPXTG motif from USA300 genomic DNA. The amplified PCR product was then ligated in frame with a c-terminal His tag into the pET 21b(+) E. coli expression vector (Novagen). The resulting construct was transformed into E. coli BL21-gold (DE3) Competent Cells
(Stratagene) and induced for protein expression for 3.5 hrs with IPTG according to the manufacturer's instructions. The induced E. coli culture was lysed by bead beating in Lysis Buffer (150 mM NaCl, 20 mM Tris pH 7.5, 1% triton-X, and Roche protease inhibitor EDTA-free tablets). Cleared lysates were then incubated with NiNta resin (Qiagen) in the presence of 10 mM Imidazole for 1 hr at 4°C to pull-down the recombinant CIfA protein. Expression of exogenous CIfA expressed in E. coli and incubation with S. aureus lysate_
Expression and Purification of S. aureus cell surface SDR proteins CIfA, CIfB, SdrC, SdrD, SdrE in E.coli: The CIfA, CIfB, SdrC, SdrD and SdrE genes were PCR amplified from the sequence encoding the mature start of the protein to the sequence encoding the glycine in the LPXTG motif from USA300 genomic DNA and ligated in- frame with an N-terminal Unizyme tag into the ST239 Vector (Genentech). The constructs were transformed into E.coli 58F3 (Genentech), induced for protein expression and subsequently purified. NiNta capture of NT Unizyme tagged SDR proteins: 500ug of purified N- terminal Unizyme tagged SDR proteins (CIfA, CIfB, SdrC, SdrD, SdrE) were diluted in PBS containing protease inhibitors (EDTA-free) and incubated with NiNta resin (Qiagen) for 1.5 hr at 4°C. NiNta resin with the captured Unizyme tagged SDR protein was then washed once with wash buffer (50 mM NaEbPCU, 30OmM NaCl; pH 8.0).
Modification of E.coli produced SDR proteins by S. aureus Iy sate: A 25 ml culture was started from an overnight culture of ΔPan Sdr mutant (CIfA-CIfB- SdrCDE-null; gift of Tim Foster, Trinity College Dublin) Newman S. aureus (starting ODβoo of 0.15) and grown in TSB for 3 hrs (exponential phase) 37°C, 200 rpm. The exponential phase culture was then resuspended in 1 ml of PBS and lysed with 200 ug/ml lysostaphin in the presence of 250 units of Benzonase Nuclease (Novagen) at 37°C for 30 minutes. The lysates were cleared of debris by spinning down at maximum speed in a micro-centrifuge for 10 minutes at 4°C. Modification of NiNta captured E.coli SDR protein was carried out by incubation with cleared ΔPan Sdr mutant S. aureus lysates for 1 hr at 37°C. Western Blotting of modified E.coli SDR protein: Non- modified or modified NiN ta captured E.coli SDR protein samples were then washed 3x with wash buffer (50 mM NaH2PO4, 30OmM NaCl, 10 mM Imidazole; pH 8.0), prepared for Western Blotting and run on an 8% Tris Glycine Gel (Invitrogen). Western blots were blotted with either the rFl antibody or an anti-Unizyme antibody (Genentech).
Identification of SDR domain as antigen for rFl
S. aureus expression of MBP-SD Constructs: The maltose binding protein (MBP) gene was PCR amplified from the pMAL-c5x vector (New England BioLabs [NEB], Ipswich, MA, USA) from the sequence encoding the start of the mature protein until the sequence encoding the end of the Factor Xa cleavage site. The varying lengths of c-terminal His tagged SD (SD, SDS, DSD, SDSD, SDSDS, SDSDSD) were synthesized as single stranded oligonucleotides and annealed together to make double stranded dna. The Sdr region of the CIfA gene was PCR amplified from the sequence encoding the beginning (560D) of the Sdr region and included up to either the sequence encoding 618A or 709S of the SD region followed by the dna sequence coding for a His Tag from the respective plasmids pTet.ClfA.SD618A or pTet.ClfA.SD709S (Genentech). As a control, the sequence encoding the A domain of the CIfA gene from the beginning of the mature protein until the sequence encoding the end of the A domain (538G) followed by the sequence coding for a His Tag was PCR amplified from the plasmid pTet.ClfA.Adom.538G (Genentech). The MBP insert along with one of the various SD inserts or CIfA A domain were ligated into the pTet S. aureus expression vector (pSASlO from Genentech). The resulting constructs were then electroporated into the S. aureus RN4220 Δ sortase (sortase deletion mutant strain in the RN4220 background).
A 20 ml culture of either the electroporated RN4220 Δ sortase or RN4220 Δ sortase empty (not carrying a pTet expression vector) was inoculated from an overnight culture (starting ODβoo of 0.15), grown for 1 hr in trypticase soy broth (TSB) supplemented with glucose (2 g/L) and then induced for protein expression for 2 hrs with anhydrotetracycline (200 ng/ml). At the end of the induction period, the S.
aureus culture was resuspended in Column Buffer (150 mM NaCl, 2OmM Tris pH 7.5 and Roche protease inhibitor EDTA-free tablets) and lysed with 200 ug/ml lysostaphin in the presence of 250 units of Benzonase Nuclease (Novagen) at 37°C for 30 minutes. The lysates were cleared of debris by spinning down at maximum speed in a microcentrifuge for 10 minutes at 4°C. The cleared lysates were then incubated with amylose resin (NEB) along with a final EDTA concentration of ImM for 1.5 hrs at 4°C to capture the expressed MBP-SD proteins.
Western Blotting of S. aureus expressed MBP-SD Constructs: Amylose resin with the captured MBP-SD proteins were washed three times with Column Buffer, further prepared for Western blotting analysis and run on an 8% Tris-glycine gel. Western blots were blotted with either the rFl antibody, an anti-penta His antibody (Qiagen) or an anti-MBP antibody (NEB).
RESULTS rFl reacts to a unique family of SDR (Ser-Asp-repeat) proteins in S. aureus and S. βpidβrmidis
A commercial teichoic acid preparation and cell wall lysate (WTA) of S.
aureus (USA300 strain) was tested for binding to rFl after immunoprecipitation. rFl binds to several components of the commercial teichoic acid preparation (figure 6A, left panel) and of the cell wall lysate of S. aureus (figure 6B, left panel). Using mass spectrometry these components of the WTA preparation and cell wall lysate were identified as CIfA (SdrA), CIfB (SdrB), SdrC, SdrD and SdrE (figure 6A, right panel and figure 6B, right panel)
A cell wall lysate of S. epidermidis was tested for binding to rFl after immunoprecipitation. Figure 6C (left panel) shows binding of rFl to several components of a cell wall lysate of S. epidermidis. These components were not identified with a control antibody. Using mass spectrometry these cell wall components were identified as SdrF, SdrG and SdrH (figure 6C right panel).
Exogenous CIfA expression in S. aureus and E.coli
Exogenous CIfA expressed in S. aureus is reactive to rFl, whereas CIfA expressed in E. coli was not (figure 7A). However, incubation of E. coli expressed Sdr proteins CIfA (SdrA), CIfB (SdrB), SdrC, SdrD and SdrE with S. aureus lysate regained rFl reactivity (figure 7B). rFl binds to SDR domains expressed in S. aureus
rFl antibody binds to CIfA Sdr regions consisting of the CIfA 560D-618S and CIfA 560D-709S (figure 8) expressed in S. aureus. rFl does not bind to the A-domain of CIfA or to small peptide sequences consisting of up to three SD repeats.
Example 4
METHODS
Cloning of the variable regions of rFl into pRK vector
Phusion DNA polymerase, restriction enzymes EcoRV, Kpnl, PvuII, Apal, Agel, and Ahdl, T4 DNA ligase were purchased from New England BioLabs, Ipswich, MA, USA. Pfu DNA polymerase, Quick change II Site-Directed Mutagenesis Kit were purchased from Stratagene/Agilent Technologies, Santa Clara, California, USA. 2% agarose gel was purchased from Invitrogen, Carlsbad, California, USA. pRK vectors pRK.LPG3.HuKappa and pRK.LPG4.HumanHC were obtained from
Genentech/Roche, South San Francisco, California, USA.
The variable domains of heavy and light chains of rFl Mab from the pCPEO vectors were placed into the pRK mammalian expression vectors. Polymerase chain reaction (PCR) was performed in a total volume of 50 μl using Pfu DNA polymerase according to standard PCR procedures. VH was amplified with the primers YiHCF) 5'- ATG GCT GAG GTG CAG CTG GTG GAG TCT G-3' (SEQ ID NO:18) and YiH CR2 5'- GAA CAC GCT GGG GCC CTT GGT GCT GGC ACT CGA GAC TGT GAC CAG GGT GCC AGG T*CC CCA G-3' (SEQ ID NO:19) (the restriction sites of PvuII and Apal are underlined and the * indicates the single nucleotide G to T change to eliminate the internal Apal site) and VL was amplified with the primers YiLCF 5'-CGG CTC
GAC CGA TAT CCA GCT GAC CCA GAG-3' (SEQ ID NO:20) and YiLCR 5'-GAT TTC CAG CTT GGT ACC CTG GCC G-3' (SEQ ID NO:21) (the EcoRV and Kpnl are underlined). Unique PCR products with 393 (VH) and 328 (VL) bp, respectively, were directly digested by PvuII and Apal for VH, ECORV and Kpnl for VL, followed by Gel purification (Invitrogen, Catalog# K2100-12). VH and VL were individually ligated into pRK vector fragments of pRK/Pvull, Apal for Heavy chain and pRK/EcoRV, Kpnl for light chain using T 4 DNA ligase. The DNA plasmids were confirmed by restriction enzyme digestion patterns, i.e. ΓFIVH released ~300 bp and 5.8 kb bands by Agel, whereas ΓFIVL shown 2.3 and 3.1 kb bands by Ahdl on 2% agarose gel.
Chemical stress testing
By comparing antibody primary sequence data to experimentally observed degradation events, it has become clear that certain sequence motifs may be prone to degradation (i.e, aspartate isomerization at DD, DG, and DS sequences and asparagine deamidation at NG sequences). If such a degradation "hot spot" appears in the CDR of an antibody, binding and potency may be negatively impacted. For molecules containing hot spots, chemical stress testing provides a way to assess the susceptibility of these motifs to degradation by putting the antibody into a platform formulation buffer and comparing a control sample to one stressed at 4O0C for two weeks. If degradation is observed the primary sequence can be re-engineered to remove the hot spot.
After the sample is stressed for two weeks at 4O0C, a variety of analytical assays are performed to assess where and how much degradation occurred. An imaged capillary isoelectric focusing (icIEF) analysis was performed to examine charge variants and the intact and reduced antibody mass was verified using mass spectrometry, and an LC-MS/MS peptide map was performed to obtain site-specific degradation information.
Mutagenesis
The rFl pRK plasmids underwent a series of site- directed mutagenesis to stabilize the rFl Mab by N (AAC) 53S (AGC) in heavy chain CDR2 with using FHV 5'- GGT GGC CAG CAT CAA CAG CGG CAA CAA CCC CTA CTA CG-3' (SEQ ID
NO:22) and RHV 5'-CGT AGT AGG GGT TGT TGC CGC TGT TGA TGC TGG CCA CC-3' (SEQ ID NO:23) (mutagenesis site is underlined) via Quik change II Site- Directed Kit. The mutagenesis variant was sequenced. RESULTS The primary sequence of antibody rFl contained one potential asparagine deamidation site in light chain CDR2: NNGNN (SEQ ID NO:24). Stress testing revealed an increase of deamidation in stressed samples at N53 (numbering according to Kabat, 1991). Site-directed mutagenesis was performed to stabilize the rFl Mab by N (AAC, (SEQ ID NO:25)) to 53S (AGC, (SEQ ID NO:26)) substitution in heavy chain CDR2. Sequencing of the mutagenesis variant confirmed an N53S mutation.
Example 5
Development of Cys variants for antibody-drug conjugate (ADC)
applications
The rFl pRK plasmids underwent a series of site-directed mutagenesis with oligos of rFlpRK.LC(205/210)VCF (468075) 5'-GGG CCT GAG CTC GCC CTG CAC AAA GAG CTT CAA CAG-3' (SEQ ID NO:27) and rFlpRK.LC(205/210)VCR
(468076) 5'-CTG TTG AAG CTC TTT GTG CAG GGC GAG CTC AGG CCC-3' (SEQ ID NO:28) (Cys mutant is underlined) to generate the light chain linkers of rFl thioMab, and rFlpRK.HCN53S.Al2lCF (468464) 5'-CTG GTC ACA GTC TCG AGT TGC AGC ACC AAG GGC CCA TC-3' (SEQ ID NO:29) and
rFlpRK.HCN53S.Al2lCR (468465) 5'-GAT GGG CCC TTG GTG CTG CAA CTC GAG ACT GTG ACC AG-3' (SEQ ID NO:30) (Cys mutant is underlined) to make the heavy chain linkers of rFl thioMab via the Stratagene's Site-Directed method. Light chain V205C and heavy chain A114C were confirmed by sequencing of the variants (figure 9). Brief description of the drawings
Figure 1: Heavy chain and light chain sequences of antibody Fl Figure 2: Fl antibody binds to LTA preparations from several Gram-positive bacteria, (a) LTA preparations were derived from Sigma and tested in a capture ELISA with a mouse polyclonal anti-LTA or (b) a highly purified set of LTA preparations derived from W. Fischer. D25, a human anti-RSV antibody was used as non-specific negative control and a mouse monoclonal anti-LTA antibody as a positive control.
Figure 3: Recombinant Fl antibody binds to S. aureus but not to S. pneumoniae, (a) Bacteria were incubated with Fl antibody, or a control IgG (D25, a human anti-RSV antibody) or without first antibody (IgG-PE only). After washing the secondary antibody was added (IgG-PE). (b) 6 clinical isolates were tested in two separate experiments for the binding of Fl. Tested were a PVL+ strain (SA-I), 3 regular (SA-2 SA-3 and SA-4), and 2 MRSA strains (SA-5 and SA-6).
Figure 4: (a) Binding of rFl antibody to 14 S. aureus strains, (b) rFl antibody binds to S. epidermidis but not to Bacillus subtilis, Enterococcus faecalis, Listeria monocytogenes and Streptococcus pyogenes.
Figure 5: (a) rFl antibody binds to MRSA in different growth stages, Iso C: isotype control, Med: media control (b) rFl antibody binds to MRSA isolated from infected tissue.
Figure 6: rFl antibody binds to SDR proteins, (a) Immunoprecipitation (IP) of a commercial teichoic acid preparation of S. aureus (Wood 46 strain) with rFl or isotype control antibody, followed by Western blotting with rFl antibody (left) and mass spectrometry analysis of fragments from the WTA preparation bound by rFl antibody (right), (b) Immunoprecipitation (IP) of cell wall lysate of S. aureus (USA300 strain) with rFl or control antibody, followed by Western blotting (WB) with rFl antibody (left) and mass spectrometry analysis of cell wall fragments (USA300 strain) bound by rFl antibody (right) (c) Immunoprecipitation of cell wall lysate of S. epidermidis with rFl or isotype control antibody, followed by Western blotting with rFl antibody (left), mass spectrometry analysis of cell wall fragments bound by rFl antibody (right). Figure 7: Binding of rFl to SDR proteins expressed in S. aureus and E. coli. (a)
Western blotting of S. aureus and E. coli lysates containing overexpressed His-tagged CIfA using anti-His (left) and rFl (right) antibody, (b) Western Bloting of E. coli cell lysates containing his-tagged CIfA, CIfB, SdrC, SdrD and SdrE following incubation with S. aureus lysate with rFl (top) or anti-His (bottom) antibody.
Figure 8: rFl binds to SDR domains expressed by S. aureus. Constructs expressed by S. aureus and tested for binding to rFl (left), Western blots of S. aureus lysates containing the expressed constructs with anti-MBP (maltose binding protein), anti- His and rFl antibody (right).
Figure 9: Sequences of heavy chain A114C (a) and light chain V205C (b) variants of antibody rFl. Numbering according to Kabat (1991), boxes: CDRs.
References
Diehl S.A. et al. J Immunol 180, 4805-4815 (2008)
Greenberg J. W. et al. Infection and Immunity 64, 3318-3325 (1996)
Jaleco A. C. et al. Blood 94, 2637-2646 (1999)
Kabat et al. Sequences of Proteins of Immunological interest, 5th Ed. Public Health Service, National Institute of Health, Bethesda, MD (1991)
Keller R. et al. Infect Immun 60, 3664-3672 (1992)
Kwakkenbos M et al. Nat Med accepted for publication (2009)
Moran et al. NEMJ 355, 666-674 (2006)
Polotsky V. Y. et al. Infection and Immunity 64, 380-383 (1996)
Scheeren F.A. et al. Nat Immunol 6, 303-313 (2005)
Shvarts A. et al. Genes Dev 16, 681-686 (2002)
Weidenmaier C. et al. Nat Rev Microbiol 6, 276-287 (2008)

Claims

Claims
1. An antibody or functional part thereof or immunoglobulin chain or functional equivalent thereof, which comprises:
- a heavy chain CDRl sequence comprising a sequence which has at least 70% sequence identity to the sequence RFAMS, and/or
- a heavy chain CDR2 sequence comprising a sequence which has at least 70% sequence identity to the sequence SINNGNNPYYARSVQY, and/or
- a heavy chain CDR3 sequence comprising a sequence which has at least 70% sequence identity to the sequence DHPSSGWPTFDS, and/or
- a light chain CDRl sequence comprising a sequence which has at least 70% sequence identity to the sequence RASENVGDWLA, and/or
- a light chain CDR2 sequence comprising a sequence which has at least 70% sequence identity to the sequence KTSILES, and/or
- a light chain CDR3 sequence comprising a sequence which has at least 70% sequence identity to the sequence QHYXRFPYT, wherein X is I or M.
2. An antibody or functional part or immunoglobulin chain or functional equivalent according to claim 1, having a heavy chain sequence comprising a sequence which has at least 70% sequence identity to the sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINN
GNNPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWP TFDSWGPGTLVTVSS and/or having a light chain sequence which has at least 70% sequence identity to the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSIL ESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRT
V, wherein X is I of M.
3. An antibody or functional part or immunoglobulin chain or functional equivalent according to claim 1, having a heavy chain sequence comprising a sequence which has at least 70% sequence identity to the sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINN
GNNPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWP TFDSWGPGTLVTVSS and/or having a light chain sequence which has at least 70% sequence identity to the sequence DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYEQKPGKAPNLLIYKTSIL ESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRA
, wherein X is I of M.
4. An antibody or functional part or immunoglobulin chain or functional equivalent according to claim 1, having a heavy chain sequence comprising a sequence which has at least 70% sequence identity to the sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINN GNNPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWP TFDSWGPGTLVTVSS and/or having a light chain sequence which has at least 70% sequence identity to the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSIL ESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKVEIKRT
V, wherein X is I of M.
5. An antibody or functional part or immunoglobulin chain or functional equivalent according to claim 1, having a heavy chain sequence comprising a sequence which has at least 70% sequence identity to the sequence
EVQLVESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINN GNNPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWP TFDSWGPGTLVTVSS and/or having a light chain sequence which has at least 70% sequence identity to the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSIL ESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRT
V, wherein X is I of M.
6. An antibody or functional part or immunoglobulin chain or functional equivalent according to claim 1, having a heavy chain sequence comprising a sequence which has at least 70% sequence identity to the sequence
EVQLVESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINN GNNPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWP TFDSWGPGTLVTVSS and/or having a light chain sequence which has at least 70% sequence identity to the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSIL ESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRA
, wherein X is I of M.
7. An antibody or functional part or immunoglobulin chain or functional equivalent according to claim 1, having a heavy chain sequence comprising a sequence which has at least 70% sequence identity to the sequence
EVQLVESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINN GNNPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWP
TFDSWGPGTLVTVSS and/or having a light chain sequence which has at least 70% sequence identity to the sequence
DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYRQKPGKAPNLLIYKTSIL ESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKVEIKRT
V, wherein X is I of M.
8. An antibody or functional part or immunoglobulin chain or functional equivalent according to any one of claims 1-7, wherein an asparagine has been replaced by another amino acid.
9. An antibody or functional part or immunoglobulin chain or functional equivalent according to claim 8, wherein said asparagine is an asparagine at position 53 of the heavy chain, whereby the amino acid numbering is according to Kabat (1991).
10. An antibody or functional part or immunoglobulin chain or functional equivalent according to claim 8 or 9, wherein said other amino acid is serine.
11. An antibody or functional part or immunoglobulin chain or functional equivalent according to any one of claims 1-10, wherein at least one amino acid other than cysteine has been replaced with cysteine.
12. An antibody or functional part or immunoglobulin chain or functional equivalent according to claim 11, wherein said at least one amino acid other than cysteine is valine at light chain position 205 and/or valine at light chain position 110, and/or alanine at heavy chain position 114, whereby the amino acid numbering is according to Kabat (1991).
13. An antibody or functional part or immunoglobulin chain or functional equivalent according to any one of claims 1-12, which is a human antibody.
14. An isolated antibody that binds to in vivo-grown S. aureus.
15. The antibody of claim 14, wherein said antibody is human.
16. An antibody or functional part or immunoglobulin chain or functional equivalent capable of binding an SD-repeat dependent epitope.
17. An antibody or functional part or immunoglobulin chain or functional equivalent capable of binding to S. aureus CIfA, CIfB, SdrC, SdrD and SdrE.
18. An antibody or functional part or immunoglobulin chain or functional equivalent which is capable of competing with an antibody or functional part or
immunoglobulin chain or functional equivalent according to any one of claims 1-13 for binding to a Staphylococcus species.
19. An isolated, synthetic or recombinant nucleic acid sequence with a length of at least 15 nucleotides, or a functional equivalent thereof, encoding at least one CDR sequence of an antibody or functional part or immunoglobulin chain or functional equivalent according to any one of claims 1-13.
20. An isolated, synthetic or recombinant nucleic acid sequence, or a functional
equivalent thereof, comprising a sequence which has at least 70% sequence identity to a sequence selected from the group consisting of cgctttgccatgagc, tcgatcaataatgggaataacccatactacgcacggtcggtacaatac,
gatcaccctagtagtggctggcccacctttgactcc, cgggccagtgaaaacgttggtgactggttggcc, aagacatctattctagaaagt and caacactatatacgtttcccgtacact.
21. A nucleic acid sequence or functional equivalent according to claim 20, wherein said nucleic acid sequence or functional equivalent comprises a sequence which has at least 70% sequence identity to at least part of a nucleotide sequence as depicted in Figure 1, said part having at least 15 nucleotides and encoding at least one CDR region.
22. An isolated, synthetic or recombinant nucleic acid sequence, or a functional
equivalent thereof, comprising a sequence encoding an amino acid sequence which has at least 70% sequence identity to the sequence RFAMS, and/or at least 70% sequence identity to the sequence SINNGNNPYYARSVQY, and/or at least 70% sequence identity to the sequence DHPSSGWPTFDS, and/or at least 70% sequence identity to the sequence RASENVGDWLA, and/or at least 70% sequence identity to the sequence KTSILES, and/or at least 70% sequence identity to the sequence QHYXRFPYT, wherein X is I or M, and/or at least 70% sequence identity to the sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTLSRFAMSWVRQAPGRGLEWVASINN GNNPYYARSVQYRFTVSRDVSQNTVSLQMNNLRAEDSATYFCAKDHPSSGWP TFDSWGPGTLVTVSS, and/or at least 70% sequence identity to the sequence DIQLTQSPSALPASVGDRVSITCRASENVGDWLAWYEQKPGKAPNLLIYKTSIL ESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYXRFPYTFGQGTKLEIKRT
V, wherein X is I or M.
23. An antibody or functional part or an immunoglobulin chain or functional
equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to any one of claims 1-22, for use as a medicament and/or prophylactic agent.
24. An antibody or functional part or an immunoglobulin chain or functional
equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to any one of claims 1-22, for use as a medicament and/or prophylactic agent for at least in part treating and/or preventing a Gram-positive bacterium- related disorder.
25. Use of an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to any one of claims 1-22 for the preparation of a medicament and/or prophylactic agent for at least in part treating and/or preventing a Gram-positive bacterium-related disorder.
26. A pharmaceutical composition comprising an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to any one of claims 1-22 and a pharmaceutical acceptable carrier, diluent or excipient.
27. An isolated or recombinant antibody producing cell capable of producing an
antibody or functional part or immunoglobulin chain or functional equivalent according to any one of claims 1-18.
28. A method for producing an antibody or functional part or immunoglobulin chain or functional equivalent according to any one of claim 1-18, comprising providing a cell with a nucleic acid sequence or functional equivalent according to any one of claims 19-22 and allowing said cell to translate said nucleic acid sequence or functional equivalent according to any one of claims 19-22, thereby producing said antibody or functional part or immunoglobulin chain or functional equivalent according to any one of claim 1-18.
29. A method according to claim 28, further comprising harvesting, purifying and/or isolating said antibody or functional part or immunoglobulin chain or functional equivalent according to any one of claim 1-18.
30. Use of an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to any one of claims 1-18 for diagnosis of a Staphylococcus infection.
31. Use of an antibody or functional part or an immunoglobulin chain or functional equivalent thereof or a nucleic acid sequence or functional equivalent thereof according to any one of claims 1-18 for detecting S. aureus and/or S. epidermidis.
32. An antibody or functional part thereof or an immunoglobulin chain or functional equivalent thereof according to any one of claims 1-18 for use in the diagnosis of a Staphylococcus infection.
33. A method for isolating S. aureus and/or S. epidermidis bacteria from a solution using an antibody or functional part or an immunoglobulin chain or functional equivalent thereof according to any one of claims 1-18.
PCT/NL2010/050456 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds WO2011008092A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
EP10734844.3A EP2454284B1 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds
MX2014012186A MX350234B (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds.
ES10734844.3T ES2673323T3 (en) 2009-07-15 2010-07-15 Specific binding compounds to gram positive bacteria
SG2012002622A SG177653A1 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds
EA201390967A EA031447B1 (en) 2009-07-15 2010-07-15 Antibodies that bind with sdr proteins and methods of use thereof
DK10734844.3T DK2454284T3 (en) 2009-07-15 2010-07-15 GRAM POSITIVE BACTERIA-SPECIFIC BINDING COMPOUNDS
NZ598063A NZ598063A (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds
CA2768204A CA2768204A1 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds
BR112012000953A BR112012000953A8 (en) 2009-07-15 2010-07-15 gram-positive bacterial binding antibodies, nucleic acid sequence, their uses and their method of production, isolated or recombinant antibody-producing or isolated cells, compositions, and method of isolating bacteria
PL10734844T PL2454284T3 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds
CN201080041138.6A CN102666583B (en) 2009-07-15 2010-07-15 Gram positive bacterium specificity combinating compound
SI201031701T SI2454284T1 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds
AU2010271582A AU2010271582B2 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds
JP2012520555A JP6192294B2 (en) 2009-07-15 2010-07-15 Gram-positive bacteria-specific binding compounds
KR1020127003839A KR101832201B1 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds
IL217497A IL217497A (en) 2009-07-15 2012-01-12 Isolated antibodies capable of binding to gram positive bacteria, pharmaceutical compositions cormrising them, their uses and methods for producing them
ZA2012/00363A ZA201200363B (en) 2009-07-15 2012-01-17 Gram-positive bacteria specific binding compounds
IL238074A IL238074A (en) 2009-07-15 2015-04-01 Antibodies that bind to a serine-aspartate (sd) repeat (sdr) protein, pharmaceutical compositions comprising them and their use
IL242207A IL242207A0 (en) 2009-07-15 2015-10-22 Gram-positive bacteria specific binding compounds
AU2016250398A AU2016250398B2 (en) 2009-07-15 2016-10-27 Gram-positive bacteria specific binding compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22587809P 2009-07-15 2009-07-15
EP09165558.9 2009-07-15
EP09165558 2009-07-15
US61/225,878 2009-07-15

Publications (3)

Publication Number Publication Date
WO2011008092A2 true WO2011008092A2 (en) 2011-01-20
WO2011008092A3 WO2011008092A3 (en) 2011-05-26
WO2011008092A4 WO2011008092A4 (en) 2011-07-07

Family

ID=41467048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2010/050456 WO2011008092A2 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds

Country Status (24)

Country Link
US (9) US20110020323A1 (en)
EP (1) EP2454284B1 (en)
JP (3) JP6192294B2 (en)
KR (1) KR101832201B1 (en)
CN (2) CN105440133A (en)
AR (1) AR077756A1 (en)
AU (2) AU2010271582B2 (en)
BR (1) BR112012000953A8 (en)
CA (1) CA2768204A1 (en)
DK (1) DK2454284T3 (en)
EA (1) EA031447B1 (en)
ES (1) ES2673323T3 (en)
HK (1) HK1222418A1 (en)
HU (1) HUE038277T2 (en)
IL (3) IL217497A (en)
MX (1) MX350234B (en)
NZ (2) NZ598063A (en)
PL (1) PL2454284T3 (en)
SG (2) SG177653A1 (en)
SI (1) SI2454284T1 (en)
TR (1) TR201809128T4 (en)
TW (2) TWI502068B (en)
WO (1) WO2011008092A2 (en)
ZA (2) ZA201200363B (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012072814A1 (en) * 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
WO2014194247A1 (en) * 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
WO2014193722A1 (en) * 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
WO2015093949A2 (en) 2013-12-17 2015-06-25 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
US9090677B2 (en) 2009-07-15 2015-07-28 Genentech, Inc. Gram-positive bacteria specific binding compounds
WO2016090040A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
WO2016090038A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
EP2975054A4 (en) * 2013-03-12 2016-11-23 Zenyaku Kogyo Kk Anti-staphylococcus antibody, method for manufacturing same, and usage of same
EP2867258B1 (en) * 2012-07-02 2017-06-28 Bristol-Myers Squibb Company Optimization of human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2017075173A3 (en) * 2015-10-30 2017-07-27 Genentech, Inc. Anti-factor d antibodies and conjugates
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
US9822339B2 (en) 2005-12-09 2017-11-21 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
US10077427B2 (en) 2005-12-09 2018-09-18 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US10344076B2 (en) 2009-07-15 2019-07-09 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US10611829B2 (en) 2014-01-31 2020-04-07 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
US11807686B2 (en) 2017-05-30 2023-11-07 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
US11945874B2 (en) 2009-05-13 2024-04-02 Genzyme Corporation Anti-human CD52 immunoglobulins

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102559733A (en) * 2012-03-13 2012-07-11 黑龙江省科学院微生物研究所 Building method of lactococcus lactis genetic engineering bacterial strain loaded with clfA gene
AU2013341361A1 (en) 2012-11-06 2015-06-04 Medimmune, Llc Antibodies to S. aureus surface determinants
AR095199A1 (en) * 2013-03-15 2015-09-30 Genzyme Corp ANTI-CD52 ANTIBODIES
WO2016200926A1 (en) * 2015-06-09 2016-12-15 Techulon Inc. Peptide nucleic acid molecules for treatment of gram positive bacterial infection
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11280788B2 (en) 2019-01-31 2022-03-22 Fresenius Medical Care Holdings, Inc. Rapid diagnosis of peritonitis in peritoneal dialysis patients
KR102301987B1 (en) * 2019-11-14 2021-09-13 연세대학교 산학협력단 Method of screening antibody, bacteria contamination diagnosis method and bacteria contamination diagnosis kit
WO2023129822A2 (en) * 2021-12-28 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified bacterial peptidoglycan compositions and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939543B2 (en) 1997-06-16 2005-09-06 Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2009012268A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
WO2009052249A1 (en) 2007-10-19 2009-04-23 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
WO2009099728A1 (en) 2008-01-31 2009-08-13 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2192175A1 (en) 1994-06-07 1995-12-21 Ambrose Cheung Surface protein of staphylococcus aureus
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
DK0807185T3 (en) * 1995-01-30 2002-10-07 Lunamed Ag Anti-tumor preparations containing a streptococcus lipoteichoic acid
SE9602496D0 (en) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
CA2341018C (en) 1998-08-31 2012-07-31 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
ES2322409T3 (en) 1998-08-31 2009-06-19 Inhibitex, Inc. MULTICOMPONENT VACCINES AGAINST STAPHYLOCOCCUS AUREUS.
CA2341177A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US20030165527A1 (en) 1998-12-22 2003-09-04 Bengt Guss Novel fibronectin-binding protein
US20040038327A1 (en) 1999-08-31 2004-02-26 Foster Timothy J. Antibodies to polypeptides from coagulase-negative staphylococci
KR20030071861A (en) 2001-01-26 2003-09-06 인히비텍스, 인코포레이티드 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
KR100708398B1 (en) 2002-03-22 2007-04-18 (주) 에이프로젠 Humanized antibody and process for preparing same
AU2003274972A1 (en) 2002-09-13 2004-04-30 Inhibitex, Inc. Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
US20040151737A1 (en) 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
CN1787839B (en) 2003-03-07 2011-09-28 惠氏控股公司 Polysaccharide - staphylococcal surface adhesion carrier protein conjugates for immunization against nosocomial infections
CA2526753A1 (en) * 2003-05-29 2004-12-23 Inhibitex, Inc. Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
WO2007100580A2 (en) 2006-02-22 2007-09-07 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
AU2007255384B2 (en) * 2006-06-06 2012-09-27 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
MX2009010389A (en) * 2007-03-30 2010-01-20 Medimmune Llc Antibody formulation.
CN101302504B (en) * 2007-05-11 2011-12-21 上海高科联合生物技术研发有限公司 Method for purifying lysostaphin by antibody affinity chromatography
WO2009045434A2 (en) * 2007-10-01 2009-04-09 The Texas A & M University System Inhibitors of staphylococcus aureus sdrd protein attachment to cells and uses therefor
CN101983067B (en) 2008-01-31 2017-07-11 近都柏林之伊丽莎白皇后神圣及不可分割的三位一体学院之教务长,研究员和学者 The treatment of microorganism infection
WO2010005513A2 (en) 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
TWI469789B (en) 2009-06-22 2015-01-21 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
HUE038277T2 (en) 2009-07-15 2018-10-29 Aimm Therapeutics Bv Gram-positive bacteria specific binding compounds
ES2625979T3 (en) 2009-07-16 2017-07-21 Glaxosmithkline Biologicals S.A. Infection treatment

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939543B2 (en) 1997-06-16 2005-09-06 Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2009012268A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
WO2009052249A1 (en) 2007-10-19 2009-04-23 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
WO2009099728A1 (en) 2008-01-31 2009-08-13 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DIEHL S.A. ET AL., J IMMUNOL, vol. 180, 2008, pages 4805 - 4815
GREENBERG J.W. ET AL., INFECTION AND IMMUNITY, vol. 64, 1996, pages 3318 - 3325
JALECO A.C. ET AL., BLOOD, vol. 94, 1999, pages 2637 - 2646
KELLER R. ET AL., INFECT IMMUN, vol. 60, 1992, pages 3664 - 3672
KWAKKENBOS M ET AL., NAT MED, 2009
KWAKKENBOS M. ET AL., NAT MED IN PRESS, 2009
MORAN ET AL., NEMJ, vol. 355, 2006, pages 666 - 674
POLOTSKY V.Y. ET AL., INFECTION AND IMMUNITY, vol. 64, 1996, pages 380 - 383
SCHEEREN F.A. ET AL., NAT IMMUNOL, vol. 6, 2005, pages 303 - 313
SHVARTS A. ET AL., GENES DEV, vol. 16, 2002, pages 681 - 686
WEIDENMAIER C. ET AL., NAT REV MICROBIOL, vol. 6, 2008, pages 276 - 287

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273454B2 (en) 2005-12-09 2019-04-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
US10077427B2 (en) 2005-12-09 2018-09-18 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US10774308B2 (en) 2005-12-09 2020-09-15 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US9822339B2 (en) 2005-12-09 2017-11-21 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
US11945874B2 (en) 2009-05-13 2024-04-02 Genzyme Corporation Anti-human CD52 immunoglobulins
US10344076B2 (en) 2009-07-15 2019-07-09 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US9266943B2 (en) 2009-07-15 2016-02-23 Genentech, Inc. Gram-positive bacteria specific binding compounds
US9927428B2 (en) 2009-07-15 2018-03-27 Genentech, Inc. Gram-positive bacteria specific binding compounds
US9688745B2 (en) 2009-07-15 2017-06-27 Genentech, Inc. Gram-positive bacteria specific binding compounds
US9090677B2 (en) 2009-07-15 2015-07-28 Genentech, Inc. Gram-positive bacteria specific binding compounds
US9399673B2 (en) 2009-07-15 2016-07-26 Genentech, Inc. Gram-positive bacteria specific binding compounds
US9458228B2 (en) 2009-07-15 2016-10-04 Genentech, Inc. Gram-positive bacteria specific binding compounds
US9206247B2 (en) 2010-12-02 2015-12-08 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
AU2011334867B2 (en) * 2010-12-02 2016-10-13 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
WO2012072814A1 (en) * 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US9969795B2 (en) 2010-12-02 2018-05-15 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US10266591B2 (en) 2012-07-02 2019-04-23 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
EP2867258B1 (en) * 2012-07-02 2017-06-28 Bristol-Myers Squibb Company Optimization of human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
US10377824B2 (en) 2012-07-02 2019-08-13 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
US11345752B2 (en) 2012-07-02 2022-05-31 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
EP2975054A4 (en) * 2013-03-12 2016-11-23 Zenyaku Kogyo Kk Anti-staphylococcus antibody, method for manufacturing same, and usage of same
US9809645B2 (en) 2013-03-12 2017-11-07 Zenyaku Kogyo Kabushikikaisha Anti-Staphylococcus antibody, method for manufacturing same, and usage of same
US9895450B2 (en) 2013-05-31 2018-02-20 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
CN105358573A (en) * 2013-05-31 2016-02-24 基因泰克公司 Anti-wall teichoic antibodies and conjugates
WO2014194247A1 (en) * 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
WO2014193722A1 (en) * 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
CN112430266A (en) * 2013-05-31 2021-03-02 基因泰克公司 Anti-muramic acid antibodies and conjugates
CN105358573B (en) * 2013-05-31 2020-10-30 基因泰克公司 Anti-muramic acid antibodies and conjugates
JP2016532433A (en) * 2013-05-31 2016-10-20 ジェネンテック， インコーポレイテッド Anti-cell wall tycoic acid antibodies and conjugates
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
EP3381939A1 (en) * 2013-05-31 2018-10-03 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
US10570192B2 (en) 2013-05-31 2020-02-25 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
AU2014273939B2 (en) * 2013-05-31 2019-09-19 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
RU2687044C2 (en) * 2013-05-31 2019-05-06 Дженентек, Инк. Antibodies against teichoic acid conjugate and their conjugates
CN105358574A (en) * 2013-05-31 2016-02-24 基因泰克公司 Anti-wall teichoic antibodies and conjugates
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US11274152B2 (en) 2013-09-20 2022-03-15 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
WO2015093949A2 (en) 2013-12-17 2015-06-25 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
US10611829B2 (en) 2014-01-31 2020-04-07 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
CN107206102A (en) * 2014-12-03 2017-09-26 豪夫迈·罗氏有限公司 Anti-Staphylococcus aureus antibody rifamycin conjugate and application thereof
RU2731055C2 (en) * 2014-12-03 2020-08-28 Дженентек, Инк. Conjugates of antibodies to staphylococcus aureus with rifamycin and use thereof
WO2016090038A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
US20180125995A1 (en) * 2014-12-03 2018-05-10 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
WO2016090040A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
JP2018507166A (en) * 2014-12-03 2018-03-15 ジェネンテック， インコーポレイテッド Anti-STAPHYLOCOCUS AUREUS antibody rifamycin conjugate and use thereof
WO2017075173A3 (en) * 2015-10-30 2017-07-27 Genentech, Inc. Anti-factor d antibodies and conjugates
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
US11807686B2 (en) 2017-05-30 2023-11-07 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
US12049503B2 (en) 2017-05-30 2024-07-30 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors

Also Published As

Publication number Publication date
US9090677B2 (en) 2015-07-28
AU2010271582A1 (en) 2012-03-01
US20150376266A1 (en) 2015-12-31
SI2454284T1 (en) 2018-07-31
US20110020323A1 (en) 2011-01-27
US8617556B2 (en) 2013-12-31
IL217497A (en) 2015-11-30
DK2454284T3 (en) 2018-07-02
CN105440133A (en) 2016-03-30
AU2010271582A2 (en) 2013-05-16
CN102666583B (en) 2015-11-25
TW201107470A (en) 2011-03-01
US20120157665A1 (en) 2012-06-21
IL242207A0 (en) 2015-11-30
SG10201704269RA (en) 2017-06-29
BR112012000953A8 (en) 2017-12-26
US20170067880A1 (en) 2017-03-09
SG177653A1 (en) 2012-02-28
AR077756A1 (en) 2011-09-21
CA2768204A1 (en) 2011-01-20
US20160168232A9 (en) 2016-06-16
NZ598063A (en) 2014-07-25
ES2673323T3 (en) 2018-06-21
WO2011008092A3 (en) 2011-05-26
US9927428B2 (en) 2018-03-27
BR112012000953A2 (en) 2016-11-22
US20160222096A1 (en) 2016-08-04
AU2010271582B2 (en) 2016-07-28
HK1222418A1 (en) 2017-06-30
MX350234B (en) 2017-08-30
NZ616921A (en) 2015-06-26
JP2012533293A (en) 2012-12-27
US20140235828A1 (en) 2014-08-21
US9458228B2 (en) 2016-10-04
EP2454284B1 (en) 2018-04-11
ZA201400644B (en) 2015-10-28
PL2454284T3 (en) 2018-09-28
TR201809128T4 (en) 2018-07-23
KR20120065326A (en) 2012-06-20
IL217497A0 (en) 2012-02-29
US9399673B2 (en) 2016-07-26
TW201610153A (en) 2016-03-16
KR101832201B1 (en) 2018-02-28
US20130253175A1 (en) 2013-09-26
US20180292391A1 (en) 2018-10-11
EA031447B1 (en) 2019-01-31
EA201390967A1 (en) 2014-01-30
ZA201200363B (en) 2014-06-25
HUE038277T2 (en) 2018-10-29
JP6192294B2 (en) 2017-09-06
US20130261293A1 (en) 2013-10-03
TWI502068B (en) 2015-10-01
US9688745B2 (en) 2017-06-27
EP2454284A2 (en) 2012-05-23
AU2016250398B2 (en) 2018-09-27
AU2016250398A1 (en) 2016-11-17
IL238074A (en) 2016-06-30
JP2018134089A (en) 2018-08-30
CN102666583A (en) 2012-09-12
WO2011008092A4 (en) 2011-07-07
JP2016135771A (en) 2016-07-28
US9266943B2 (en) 2016-02-23

Similar Documents

Publication Publication Date Title
US9927428B2 (en) Gram-positive bacteria specific binding compounds
JP7041628B2 (en) Antibody molecules that specifically bind to lipopolysaccharide-drug conjugates and their use
KR20170136637A (en) Anti-Staphylococcus aureus antibody formulation
KR20170137111A (en) s. Antibodies directed against immunoglobulin binding proteins of Aureus
BEAUMONT et al. Patent 2768204 Summary
Troisi Isolation and characterization of highly functional human monoclonal antibodies against Neisseria gonorrhoeae and SARS-CoV-2

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080041138.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10734844

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 217497

Country of ref document: IL

Ref document number: MX/A/2012/000625

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2012520555

Country of ref document: JP

Ref document number: 2768204

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010271582

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010734844

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1380/CHENP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20127003839

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2010271582

Country of ref document: AU

Date of ref document: 20100715

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012000953

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 201390967

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 238074

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 242207

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 112012000953

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120113